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ABSTRACT 
Koesters, Andrew G.  Ph.D.  Biomedical Sciences PhD Program, Wright State 
University, 2014.  Rab3A as a Modulator of Homeostatic Synaptic Plasticity. 
 
 
The nervous system is faced with perturbations in activity levels 
throughout development and in disease or injury states.  Neurons need to adapt 
to these changes in activity, but also need to maintain circuit firing within a 
normal range to stabilize the network from becoming too excited or too 
depressed.  Homeostatic synaptic plasticity, the compensatory increase or 
decrease in synaptic strength as a result of excessive circuit inhibition or 
excitation, is a mechanism that the nervous system utilizes to keep network 
activity at normal levels.  Despite intense effort, little is known about the 
mechanisms underlying homeostatic synaptic plasticity.  Numerous studies have 
implicated postsynaptic modulation of AMPA receptors, but disagreement exists 
as to which receptor subtype, GluR1 or GluR2, predominates.  Here, we 
demonstrate the completely novel finding that a presynaptic protein, Rab3A, a 
small GTPase that binds synaptic vesicles by switching between its active GTP-
bound form and its inactive GDP-bound form, is essential for the regulation of 
homeostatic synaptic plasticity in dissociated mouse cortical neuron cultures.  
Using a combination of electrophysiology, pharmacology, and 
immunohistochemistry, we show that multiple mechanisms exist to increase 
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synaptic strength in response to chronic activity deprivation, including but not 
limited to modulation of GluR1 and GluR2-containing AMPA receptors.  Despite 
the variability and complexity of underlying mechanisms mediating the change in 
synaptic strength, we consistently found that modulation of synaptic strength in 
response to chronic network activity deprivation was completely lost in the 
absence of neuronal Rab3A, and that loss of Rab3A prevented the homeostatic 
increase in GluR2 levels but not GluR1.  We conclude that there exist a biphasic 
mechanism for homeostatic synaptic plasticity, as suggested for LTP, where the 
induction (Phase 1) of the homeostatic increase in synaptic strength is first due to 
increasing GluR1-containing AMPA receptors, which is then followed by a 
Rab3A-dependent switch to GluR2-containing AMPA receptors to maintain the 
increase in synaptic strength (Phase 2). 
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I.  INTRODUCTION 
 
Synaptic Plasticity 
The nervous system is continuously confronted with altering states of 
activity.  Numerous studies over many years have demonstrated that the nervous 
system is exceptionally proficient in responding to varying degrees of stimuli to 
remodel its circuitry in order to respond and adapt to the dynamic stream of 
synaptic activity.  This process of activity-dependent modifications in synaptic 
physiology is called synaptic plasticity.  Effective functioning of this process 
underlies normal nervous system functions such as movement, thinking, learning 
and memory, and perception, but malfunction of this system could trigger a 
variety of psychiatric and neurological disorders, possibly resulting in epilepsy, 
schizophrenia, or Alzheimer’s disease. 
 Synaptic plasticity occurs in at least two forms that have opposing effects 
on synaptic physiology.  The first is Hebbian plasticity, which includes long-term 
potentiation (LTP) and long-term depression (LTD), and induces rapid, long-
lasting changes at individual synapses in response to altered activity.  LTP is 
induced by high frequency bursts of activity that strengthen synapses and LTD is 
induced by persistent, low frequency activity to weaken synapses.  This form of 
synaptic plasticity is believed to be the basis for learning and memory.  If left 
unchecked LTP and LTD may promote network instability because as synaptic 
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strength increases unchecked at individual synapses runaway excitiation could 
occur, and unregulated depression at single synapses may cause those 
synapses to drop out of the network.  The second form is homeostatic synaptic 
plasticity, the nervous system’s response to long-lasting, chronic perturbations in 
synaptic activity.  This type of plasticity is induced by chronic perturbations to 
network activity and affects synaptic networks globally to maintain synaptic 
activity within a desired range in a compensatory manner to guard against 
network hyperexcitation and silencing.     
  
Hebbian Plasticity 
 Donald Hebb first proposed his theory on the function of neurons and 
psychological processes, such as learning and memory, in 1949.  This later 
became the basis for Hebbian synaptic plasticity, which more specifically 
includes LTP and LTD.   
 Long-term potentiation is the persistent increase in synaptic strength of an 
excitatory postsynaptic neuron as a result of high-frequency stimulation of a 
synaptically connected presynaptic neuron.  Induction of LTP requires the 
activation of N-methyl-D-aspartate (NMDA) receptors (Bliss and Collingridge, 
1993) via postsynaptic depolarization due to cation influx through α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Malenka and 
Nicoll, 1999).  AMPA receptors are ionotropic and are responsible for the majority 
of excitatory neurotransmission in the brain.  NMDA receptors are also ionotropic 
but are blocked by Mg2+ at resting membrane potentials until sufficient 
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postsynaptic depolarization removes the block allowing Ca2+ influx.  Activation of 
NMDA receptors and the subsequent influx of Ca2+ into the postsynaptic neuron 
results in an increase in the dendritic spine Ca2+ concentration triggering second 
messenger activation and a signaling cascade to recruit more AMPA receptors 
into the postsynaptic membrane.  Ca2+/calmodulin-dependent protein kinase II 
(CamKII) has been implicated as a major player in NMDAR-dependent LTP 
induction (Lisman et al., 2002; Malenka and Nicoll, 1999).  Other potential 
signaling molecules involved in LTP include other kinases, such as protein 
kinase A (PKA) (Lynch, 2004), protein kinase C (PKC) (Bliss and Collingridge, 
1993; Hu et al., 1987; Linden and Routtenberg, 1989; Malenka and Nicoll, 1999; 
Malinow et al., 1989), protein kinase M zeta (PKMζ) (Hrabetova and Sacktor, 
1996; Ling et al., 2002), proto-oncogene tyrosine-protein kinase (Src) (Salter and 
Kalia, 2004), mitogen-activated protein kinase (MAPK), which activates 
extracellular signal-related kinases (ERKs) (Sweatt, 2004; Thomas and Huganir, 
2004), and phosphatidylinositide 3-kinase (PI3 kinase), an important molecule for 
trafficking of AMPA receptors to hippocampal synapses in dissociated cultures 
(Man et al., 2003).  The trafficking of AMPA receptors to the synapse has been 
clearly demonstrated to be important for the expression and maintenance of LTP 
(Malenka and Bear, 2004; Malinow and Malenka, 2002; Shi et al., 2001). 
 The expression of LTP has been the focus of intense research and initially 
there was intense debate over whether it was due to a pre- or postsynaptic 
mechanism.  Presynaptic mechanisms would involve changes affecting the 
release of neurotransmitter, such as increases in vesicle loading of transmitter 
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and increases in the probability of release (Ho and Shen, 2011; Malinow and 
Tsien, 1990).  Postsynaptic mechanisms would involve synaptic modifications to 
postsynaptic receptors, such as increased insertion of AMPA receptors to 
enhance responsiveness to a stimulus.  Ultimately, evidence accumulated that 
the mechanism of increasing AMPAR numbers in response to activity-dependent 
changes is the major mechanism in the expression of LTP (Bredt and Nicoll, 
2003; Ho and Shen, 2011; Malenka and Nicoll, 1999; Malinow and Malenka, 
2002; Song and Huganir, 2002).  These changes in AMPA receptor - 
heterotetramers composed of four subunits, GluR1-4 (Greger et al., 2007) - 
expression appears to be due to phosphorylation of these receptors (Malenka 
and Bear, 2004), specifically the GluR1 subunit and its phosphorylation by 
CamKII, which triggers the insertion of receptors in the synaptic membrane 
(Hayashi et al., 2000; Lee et al., 2003).  
 Late-phase maintenance of LTP requires protein synthesis and gene 
transcription (Abraham and Williams, 2003; Lynch, 2004; Pittenger and Kandel, 
2003), but another theory is that synapses that have undergone LTP exhibit 
anatomical remodeling to preserve the changes in synaptic strength (Malenka 
and Bear, 2004).  These changes include growth of new dendritic spines, 
increases in the size of existing spines, and the splitting of spines into two 
functional synapses (Abraham and Williams, 2003; Yuste, 2011).  Molecular 
mechanisms affecting these structural changes have received considerable 
attention and when postsynaptic scaffolding proteins are overexpressed in 
dissociated cultures, there is an increase in dendritic spine size (Hering and 
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Sheng, 2001).  This has lead to a model of LTP where the induction involves 
insertion of GluR1 AMPA receptors followed by the accumulation of scaffolding 
proteins into the postsynaptic density (PSD) resulting in an increase in spine and 
PSD size (Lisman and Zhabotinsky, 2001; Luscher et al., 2000).  This model 
suggests that LTP first involves an increase in synaptic strength followed by 
growth of the synapse. 
 Long-term depression (LTD) is the long-lasting decrease in synaptic 
strength due to low-frequency stimulation of paired excitatory neurons.  As with 
LTP, LTD induction requires both AMPA and NMDA receptor activation (Dudek 
and Bear, 1992; Mulkey and Malenka, 1992) and the subsequent increase in 
NMDAR-mediated Ca2+ influx.  However, unlike LTP where the rise in [Ca2+] is 
large and sudden, Ca2+ entry to trigger LTD is slower and less drastic (Mulkey 
and Malenka, 1992).  This slow, persistent rise in [Ca2+] activates serine-
threonine protein phosphatases that de-phosphorylate AMPA receptors triggering 
their removal from the cell surface (Mulkey et al., 1994; Mulkey et al., 1993) 
(Mulkey and Malenka, 1992).  Induction of LTD is blocked by phosphatase 
inhibitors that target calcineurin and protein phosphatase 1 (PP1) in the 
postsynaptic cell (Kirkwood and Bear, 1994; Mulkey et al., 1994; Mulkey et al., 
1993).  As in LTP, LTD expression and maintenance are reliant on AMPA 
receptors.  De-phosphorylation of AMPA receptors, specifically the GluR1-
containing subtype, decreases channel open probability (Banke et al., 2000), and 
also underlies the loss of AMPA receptors at synapses by internalizing them via 
a clathrin-mediated process (Beattie et al., 2000).  Postsynaptic density protein 
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95 (PSD-95), a protein involved in the docking of AMPA receptors in the 
postsynaptic membrane, is directly bound to the postsynaptic membrane by 
palmitoylation and also binds stargazin, a protein demonstrated to traffic AMPA 
receptors to synapses (Chen et al., 2000; Schnell et al., 2002).  As evidenced by 
the overexpression and removal of PSD-95 from the synapse, AMPAR numbers 
increase and decrease, respectively (Schnell et al., 2002). 
 Long-term potentiation and long-term depression are widely believed to be 
the major cellular mechanism for learning and memory by rapidly fine-tuning 
individual synapses based on their experiences.  This constant strengthening 
and weakening of synapses has the potential, if left unregulated, to generate an 
unstable network.     
 
Homeostatic Synaptic Plasticity 
Homeostatic synaptic plasticity, a negative feedback mechanism, was first 
described in 1998 as a global compensatory change in synaptic strength 
resulting from chronic perturbations to neuronal network activity (O'Brien et al., 
1998; Turrigiano et al., 1998) and is proposed to protect against network 
instability that may be produced by LTP and LTD (Pozo and Goda, 2010).  When 
the Na+ channel blocker, tetrodotoxin (TTX), was applied to rat cortical neuron 
cultures for 48 hours to block all action potentials and chronically silence all 
synaptic activity, there was an enhancement in synaptic strength as evidenced 
by the increase in the amplitude of the postsynaptic response to a single vesicle 
release of neurotransmitter - miniature excitatory postsynaptic currents 
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(mEPSCs) - of pyramidal neurons (Turrigiano et al., 1998).  The converse effect 
was observed on mEPSC amplitude when bicuculline, a GABAA receptor 
antagonist, was applied to cultures for 48 hours to block all inhibitory 
transmission to cause global network hyperexcitation resulting in decreased 
mEPSC amplitude (Turrigiano et al., 1998).  The same compensatory effects 
were seen on cultured spinal neuron mEPSC amplitudes when AMPA receptor 
antagonists (to block all excitatory neurotransmission) or GABAA and kainate 
receptor antagonists (to increase basal excitatory synaptic activity) were 
chronically applied to cultures, and these changes in mEPSC amplitude were 
accompanied with an accumulation or decrease in synaptic AMPA receptors, 
respectively (O'Brien et al., 1998).  Unlike many forms of synaptic plasticity that 
require Ca2+ influx via postsynaptic NMDA receptors (Linden and Connor, 1995), 
the change in synaptic strength was, at least, in part due to AMPA receptor 
signaling, because cultures grown in the presence of the NMDA receptor 
antagonist, D (-)-amino-7-phosphonovalenic acid (AP5) for 48 hours resulted in 
no change in mEPSC amplitude or frequency, while 48 hour AMPA receptor 
blockade via 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) produced the same 
results observed with TTX (Turrigiano et al., 1998).   
Numerous studies since this groundbreaking discovery have focused on 
determining the mechanism of homeostatic synaptic plasticity, which in contrast 
to our extensive information on LTP and LTD mechanisms, is still not well 
understood.  Several possibilities exist as to where the site of synaptic strength 
could be modulated by the nervous system.  Presynaptic mechanisms that could 
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regulate synaptic strength include varying the number of synaptic vesicles being 
exocytosed or by altering the amount of neurotransmitter being loaded into a 
single vesicle (Pozo and Goda, 2010; Rich and Wenner, 2007).  For example, a 
decrease in network activity could activate a compensatory response mechanism 
that increases the number of exocytosed vesicles and/or increases the amount of 
neurotransmitter loaded into each vesicle resulting in an increase of synaptic 
strength, and vice versa if the network becomes hyperactive (Figure 1, #3 and 
#1, respectively).  The idea of increased vesicle exocytosis after chronic silencing 
is unlikely to produce a homeostatic change in mEPSC amplitude because 
frequency of mEPSC events would be expected to increase, which is not usually 
seen in homeostatic plasticity, and the improbable simultaneous fusion of 
vesicles would have to occur to produce an increase in mEPSC amplitude.  
Another potential mechanism for homeostatic plasticity that has received the 
most consideration and has been extensively studied, involves the bidirectional 
trafficking of glutamate receptors, specifically AMPA receptors (Figure 1, #2 and 
#4).  Several studies have demonstrated that in response to a variety of chronic 
activity perturbations, AMPA receptors are trafficked to and from the postsynaptic 
neuron’s membrane in a compensatory manner (Aoto et al., 2008; Correa et al., 
2012; Evers et al., 2010; Fu et al., 2011; Gainey et al., 2009; Soden and Chen, 
2010; Stellwagen and Malenka, 2006; Wierenga et al., 2005). 
  
GluR1 vs. GluR2 AMPA Receptors in Homeostatic Synaptic Plasticity  
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As mentioned earlier, AMPA receptor trafficking to and from the synapse 
in response to chronic activity perturbations has been well-established to be an 
important mechanism for the expression of homeostatic plasticity, but 
discrepancies exist as to which receptor subtypes are involved.  Some studies 
have shown that homeostatic synaptic plasticity requires the increased insertion 
of the GluR2-containing receptors into the postsynaptic membrane in response to 
activity deprivation (Cingolani et al., 2008; Gainey et al., 2009) while others have 
demonstrated an increase in surface GluR1-containing AMPA receptors (Ju et 
al., 2004; Stellwagen et al., 2005; Sutton et al., 2006; Thiagarajan et al., 2005), 
and some have shown increases in both GluR1 and GluR2 (Sun and Wolf, 2009; 
Wierenga et al., 2005).  The differences between which subunit is involved may 
be due to different experimental conditions, such as species (rat vs. mouse), age 
of the culture (1 week vs. 2 week), type of activity block (TTX vs. receptor block), 
length of activity block (24 hours vs. 48 hours), or cell type (Table 1), possibly 
demonstrating the existence of multiple types of homeostatic plasticity.  Another 
possibility is that a two-step process exists where GluR1-containing AMPA 
receptors are first inserted into the membrane followed by increased expression 
of GluR2-containing AMPA receptors, as suggested for LTP (Plant et al., 2006). 
  
Glia and Homeostatic Synaptic Plasticity 
More recently, glia have been implicated in homeostatic plasticity 
(Stellwagen and Malenka, 2006).  Glia have long been considered to be merely 
support cells of neurons in the nervous system, but have now been shown to 
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release tumor necrosis factor-α (TNFα) (Beattie et al., 2002) and glypican-4 
(Allen et al., 2012) to influence synaptic strength by increasing cell surface 
expression of GluR1-containing AMPA receptors (Allen et al., 2012; Stellwagen 
et al., 2005) and glial TNFα has been demonstrated to be essential for 
homeostatic synaptic plasticity (Stellwagen and Malenka, 2006).  Glial release of 
factors that are capable of increasing synaptic strength in a homeostatic manner 
by upregulating AMPA receptors into the postsynaptic membrane make them an 
intriguing candidate as a potential sensor for network activity. 
  
Rab3A:  A Small GTPase 
 Rab proteins are monomeric GTPases that form the largest branch of the 
Ras superfamily of small GTPases and exist in all eukaryotic cells (Lang and 
Jahn, 2008; Takai et al., 2001).  More than 60 members of Rabs have been 
identified in mammalian cells (Lang and Jahn, 2008) and these proteins regulate 
intracellular vesicle trafficking (Takai et al., 2001).  Rabs serve as a “switch” by 
cycling between their active GTP-bound form, where they associate with vesicles 
and assist in vesicle trafficking to the cell membrane, and their inactive GDP-
bound form, where they dissociate from vesicles and localize to the cytosol 
(Figure 2). 
 Rab3 is highly expressed in the brain (Pavlos et al., 2010) and Rab3A is 
overwhelmingly the most abundant isoform located at synapses (Fischer von 
Mollard et al., 1990).  The Rab3 subfamily, which encompasses Rab3A, Rab3B, 
Rab3C, and Rab3D, has been extensively studied in synaptic function and 
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secretion, and the four highly homologous isoforms, which share as much as 
84% homology (Cheng et al., 2002), have overlapping and redundant functions in 
vesicle exocytosis (Jahn, 2004; Pavlos and Jahn, 2011).  Despite evidence 
supporting Rab3A’s role in synaptic vesicle exocytosis, its exact function is still 
unclear.  Deletion of Rab3A (Rab3A-/-) results in mice that are viable and fertile 
(Schluter et al., 2004), and is not essential for exocytosis but rather may be 
important for regulating synaptic function and efficiency (Geppert et al., 1994; 
Geppert et al., 1997).  On the other hand, knockout of Rab3A in conjunction with 
any of the other two isoforms is lethal, while triple Rab3B, Rab3C, and Rab3D 
knockout animals were viable and fertile (Schluter et al., 2004).  Quadruple 
knockouts develop normally but die shortly after birth due to respiratory failure, 
have no changes in hippocampal synaptic morphology or mEPSC properties, but 
do exhibit a 30% decrease in evoked responses of cultured hippocampal 
neurons that appears to be due to a decrease in release probability (Schluter et 
al., 2004).  Rab3A has also been demonstrated to be necessary for PKA-
dependent presynaptic form of LTP at mossy fiber-CA3 synapses in the 
hippocampus (Castillo et al., 1997) and Rab3A-/- hippocampal neurons do not 
respond to BDNF-induced potentiation of evoked synaptic currents (Thakker-
Varia et al., 2001).  These results suggest that Rab3A is not critical for vesicle 
exocytosis, but is required for some forms of plasticity of release probability. 
 More recently, the Engisch and Rich labs have shown that Rab3A is 
important for homeostatic synaptic plasticity at the mouse neuromuscular 
junction (NMJ).  The Rab3A earlybird mouse (Rab3Aebd/ebd), named for its 
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shortened circadian rhythm, expresses a point mutation, D77G, in the Rab3A 
guanine nucleotide-binding regions.  The mutation decreases the ability of 
Rab3A to bind both GDP and GTP (Yang et al., 2007) and homeostatic 
regulation of synaptic strength at the NMJ is abolished in these animals (Wang et 
al., 2011).  Also, the homeostatic increase in synaptic strength at the NMJ is not 
accompanied by an increase in vesicular acetylcholine transporter, VAChT, or by 
an increase in postsynaptic acetylcholine receptors (Wang et al., 2011).  These 
results differ from what is generally thought to occur for homeostatic plasticity at 
central synapses where the increase in synaptic strength is accompanied by an 
increase in postsynaptic AMPA receptors (Table 1) and/or VGLUT1 expression 
(Buckby et al., 2006).  Interestingly, the ablation of Rab3A (Rab3A-/-) at the NMJ 
did not abolish, but did diminish, the response to activity blockade at these same 
synapses suggesting that other Rab3A isoforms which are present (Wang et al., 
2011) may compensate for the loss of Rab3A.  The finding that a presynaptic 
protein is important for modulating homeostatic synaptic plasticity at the mouse 
NMJ is surprising since the prevailing view from studies performed in primary 
cultures of hippocampal and cortical neurons is that homeostatic plasticity is due 
to the bi-directional regulation and trafficking of postsynaptic AMPA receptors in 
response to altered network activity.  A possible explanation for this could be that 
the mechanism for homeostatic plasticity is different at the NMJ than in the brain.  
We will address this possibility in Specific Aims 1 and 2. 
 
Rab3A and Disease  
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 Researchers looking at the synaptic pathology of Alzheimer’s Disease 
(AD) found that Rab3A expression was reduced in both the hippocampus and in 
the frontal cortex of AD patients and that in these AD patients lower Rab3A levels 
were found with both increasing duration and severity of dementia (Blennow et 
al., 1996).  Levels of Rab3A in brain tissue from AD patients are reduced in 
conjunction with the known AD-associated proteins, presenilin-1 and amyloid 
precursor protein (APP), and the reduction of these proteins are restricted to 
areas of the brain known to degenerate in AD (Davidsson et al., 2001).  More 
recently, Rab3A has been shown to be required for the assembly of a distinct 
type of vesicle involved in the transport of APP for cleavage by α-secretases 
(Szodorai et al., 2009).  Together, these data demonstrate a correlation between 
Rab3A expression and severity of dementia in AD patients and a functional role 
of Rab3A activity in regulating the transport of an AD-associated protein, APP. 
 In addition to AD, Rab3A has been linked to several other disorders of the 
nervous system.  Rab3A expression is reduced in the thalamus, the 
hippocampus, and the frontal and parietal cortex of post-mortem brains of 
schizophrenic patients (Davidsson et al., 1999), and is also decreased in the 
dorsolateral prefrontal cortex of patients with major depressive disorder (Kang et 
al., 2012).  Rab3A has also been demonstrated to regulate the membrane 
association and dissociation of α-synuclein, a protein known to accumulate in 
Lewy bodies in Parkinson’s Disease (Chen et al., 2013) suggesting that 
impairments of α-synuclein interactions with Rab3A and synaptic vesicles may 
play a role in neurodegeneration.  Deletion of Rab3A rescues the epileptic 
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phenotype seen in synapsin II knockout mice (Coleman and Bykhovskaia, 2010).  
The loss of Rab3A impairs glutamatergic excitatory synaptic transmission 
resulting in the restoration of the excitatory/inhibitory balance that is shifted to an 
overexcitable phenotype in the absence of synapsin II (Feliciano et al., 2013).  
Finally, another link between Rab3A and neurological disease is that Rab3A is 
an mRNA cargo of the translational regulator and RNA transporter, Fragile X 
mental retardation protein (Miyashiro et al., 2003) and its expression is 
decreased in cortical neuron synapses of the Fmr1 knockout mouse, a model 
mouse of Fragile X syndrome (Annangudi et al., 2010).   
 It is reasonable to believe that if the homeostatic balance and stability in 
neuronal activity is not maintained, it could lead to or complicate many disorders 
and diseases of the nervous system, including mental retardation and autism 
(Ramocki and Zoghbi, 2008; Toro et al., 2010).  One example is the Fragile X 
mental retardation protein, or FMRP, which has been linked to Fragile X 
syndrome and mental retardation, and has been shown to be essential for 
retinoic acid-dependent homeostatic increases in synaptic strength in response 
to neuronal silencing by TTX in the mouse hippocampus (Soden and Chen, 
2010).   
Disregulation of homeostatic synaptic plasticity has been associated with 
several diseases and disorders of the nervous system, schizophrenia (Dickman 
and Davis, 2009), Alzheimer’s disease (Pratt et al., 2011), epilepsy (Houweling et 
al., 2005), and Fragile X mental retardation (Soden and Chen, 2010).  
Determining the regulatory function of Rab3A, a synaptic protein implicated in 
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many neurological and psychiatric diseases would have major clinical 
applications by providing for a new therapeutic target in several nervous system 
diseases.  Here, we present the first evidence that Rab3A, a presynaptic 
molecule, is required for homeostatic synaptic plasticity.  Together these studies, 
and what is known about Rab3A, suggest Rab3A interacts with multiple 
neurological disease-associated mechanisms, although whether it is combating 
or contributing to pathology is unclear.  The fact that Rab3A has been 
demonstrated to be important for homeostatic synaptic plasticity at the 
NMJ, leads us to hypothesize that the presynaptic protein, Rab3A, is 
required for regulating synaptic strength in homeostatic plasticity at 
central synapses (Specific Aim 1). 
   
 
 
II.  MATERIALS AND METHODS 
  
The methods described below are common to all Aims except where 
noted.  Methodology specific to an Aim will be described with that particular Aim. 
 
Animals – Rab3A Colony 
 Rab3A heterozygous (Rab3A+/-) were bred at Wright State University to 
generate offspring consisting of homozygous wild-type Rab3A (Rab3A+/+), 
homozygous knock-out of Rab3A (Rab3A-/-), and Rab3A+/-.  Animals were 
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genotyped via Rab3A-targeted PCR of tail DNA using the following primer 
sequences:   
TCC TGT GAC CTC CAA CTG TG (forward) 
GGC CCA AAA CTG AGC AAC (reverse) 
and the reaction parameters: 
 1.  96ºC for 2:00 
2.  94ºC for 0:45 
3.  58ºC for 0:45                
4.  72ºC for 1:00 
      (repeat steps 2-4 for a total of 39 cycles) 
5.  72ºC for 7:00 
6.  4ºC hold 
The PCR products were separated on a 3.5% agarose gel.  The above PCR 
protocol yielded a 178 base-pair Rab3A wild-type amplicon (Figure 3, right lane) 
and a 170 base-pair Rab3A knock-out amplicon (Figure 3, left lane).  Rab3A+/- 
were determined by the presence of both the wild-type and knock-out amplicons 
(Figure 3, center lane).  Rab3A+/- progeny were bred to maintain the colony, while 
final breedings of Rab3+/+ males with Rab3+/+ females and Rab3A-/- males with 
Rab3A-/- females to produce homozygous litters to be used for experiments.  All 
experiments were performed on neuronal cultures prepared from newborn pups 
on postnatal day 0 (P0) making it impossible to genotype these animals prior to 
culture preparation.  The homozygous breedings allowed for determination of 
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genotypes of experimental animals.  All animal procedures were approved by 
Wright State University’s Laboratory Animal Care and Use Committee. 
 
Animals – Rab3A earlybird Colony 
 The breeding strategy for the Rab3A earlybird (ebd) animals was the 
same as described above:  Rab3A+/ebd were bred to maintain the colony, while 
Rab3A+/+ pairings and Rab3Aebd/ebd breedings were mated to produce Rab3A+/+ 
and Rab3Aebd/ebd progeny, respectively, for experiments.  Due to the presence of 
a single point mutation and the impossibility to simply screen for this via PCR, a 
more elaborate two-step genotyping protocol was performed utilizing PCR to 
amplify our region of interest followed by restriction digest of these amplicons 
with Bsp 1286I to reveal the Rab3A ebd point mutation.  The PCR protocol used 
the following primers: 
 TGA CTC CTT CAC TCC AGC CT (forward) 
TGC ACT GCA TTA AAT GAC TCC T (reverse) 
in a PCR reaction to amplify the region of DNA that may contain the Rab3A ebd 
point mutation.  The reaction parameters were as follows: 
1.  94ºC for 5:00 
2.  94ºC for 0:30 
3.  57ºC for 0:40                
4.  72ºC for 1:00 
(repeat steps 2-4 for a total of 35 cycles) 
5.  72ºC for 10:00 
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6.  4ºC hold 
Two microliters of the 45 μl PCR reaction were ran out on a 1.0% agarose gel 
and yielded a single product with a size of 557 base-pairs (Figure 4A).  The 
remaining 43 μl of PCR products were saved for further processing in the second 
step of the genotyping protocol.  The presence of a PCR amplicon was used to 
demonstrate successful DNA amplification for the actual screening process by 
restriction digest described below.  Once it was determined that the PCR was 
successful, the remaining PCR amplicons were purified and concentrated using 
the QIAEX II Kit (Qiagen) according to the manufacturers protocol.  Briefly, PCR 
products were transferred to separate tubes and three volumes of Buffer QX1 
were added to each tube.  Then, 10 μl of QIAEX II were added to each tube and 
incubated for 10 minutes at room temperature.  Samples were vortexed every 2 
minutes to maintain the QIAEX II in suspension.  After the incubation period, 
samples were centrifuged at 13,000 rpm for 30 seconds and the supernatant was 
poured off leaving the pellet.  The pellet was then washed twice with 500 μl of 
Buffer PE and allowed to air dry completely until the pellet was white.  After 
drying, DNA was eluted by adding 20 μl of nuclease-free H2O, vortexed to re-
suspend the pellet, and incubated at room temperature for 5 minutes.  Each 
sample was then centrifuged at 13,000 rpm for 1 minute and supernatant 
containing the purified and concentrated DNA was transferred to clean tubes.  
Samples were then subjected to restriction digest via the restriction enzyme Bsp 
1286I (New England Biolabs, Ipswich, MA) per the manufacturers protocol.  After 
restriction digest, samples were ran out on a 3.0% agarose gel yielding 402 and 
B. 
A. 
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155 base-pair bands for Rab3A wild-type (earlybird colony) (Figure 4B, left lane) 
and 402, 104, and 51 base-pair bands for the Rab3A earlybird mutation (Figure 
4B, right lane).  Heterozygotes were determined by the presence of all the bands 
(Figure 4B, center lane). 
 
Primary Culture of Mouse Cortical Neurons 
 Dissociated cultures of mixed neuronal and glial populations were 
prepared from P0 Rab3A-/- and Rab3Aebd/ebd neonates, and compared with 
cultures from wild-type mice from their respective colonies.  Wild-type cultures 
were produced from each heterozygote colony due to the different genetic 
backgrounds of the Rab3A KO and Rab3A ebd mice.  Each culture was prepared 
from cortices harvested from two animals.  Pups were euthanized by decapitation 
and brains were quickly removed from the skull and pinned at the cerebellum to a 
chilled Sylgard petri dish.  To prevent contamination of cortical neurons with 
hippocampal neurons, the hippocampi from both hemispheres were removed and 
discarded and cortices were dissected out and placed into 1 ml of chilled 
Neurobasal-A media (Gibco), osmolarity adjusted to 270 mOsm, and 
supplemented with DNAse (Fisher ThermoScientific).  Tissue digestion was 
carried out by the addition of papain (Worthington Biochemical) at 20 units/ml 
and incubated in a 37°C H2O bath for 20 minutes with gentle stirring.  After 
digestion, cortices were triturated very gently 3-5 times with a fire-polished 
Pasteur pipette, filtered through a 100 μm cell strainer (Corning Falcon) to 
remove chunks of tissue, and transferred to a clean, sterile 15 ml conical tube.  
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The cell suspension was then centrifuged at 1100 rpm for 2 minutes, supernatant 
was carefully removed and discarded, and the pellet resuspended with room 
temperature Neurobasal-A media (270 mOsm), supplemented with 5% fetal 
bovine serum (FBS; promotes glial growth but is toxic to neurons), 2% B-27 
supplement to promote neuronal growth (Gibco), L-glutamine, and gentamicin.  
Neurons were counted and plated onto 12 mm coverslips pre-coated with poly-L-
lysine (Corning) to produce a high density culture.  The culture media for the first 
day (0 DIV) was the same as the above Neurobasal-A media supplemented with 
FBS, B-27, L-glutamine, and gentamicin, and was switched after 24 hours (1 
DIV) to media consisting of Neurobasal-A (270 mOsm), 2% B-27, and L-
glutamine and FBS was excluded to avoid its toxic effects on neuronal viability 
and health (Stellwagen and Malenka, 2006).  Cells were maintained in culture for 
13-14 DIV and half of the media was changed twice weekly and experiments 
were performed at 13-14 DIV.  Two days prior to experiments, TTX (500 nM; 
Tocris), a potent Na+ channel blocker, was added to some cultures to chronically 
silence all network activity and induce homeostatic synaptic plasticity 
mechanisms, while sister cultures not receiving TTX treatment served as 
untreated controls.   
 
Whole-Cell Voltage Clamp to Record mEPSCs 
 At 13-14 DIV, mEPSCs from TTX-treated and control sister cultures of 
Rab3A+/+ or Rab3A-/- neurons from the Rab3A+/- colony, or Rab3A+/+ or 
Rab3Aebd/ebd neurons from the Rab3A+/ebd colony were recorded from via whole-
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cell voltage clamp to assess the role of Rab3A in homeostatic synaptic plasticity.  
Recordings were taken from pyramidal neurons, which were identified visually as 
those cells exhibiting a prominent apical dendrite; images were taken of all cells 
recorded from (Figure 5).  Cells were continuously perfused with a solution 
consisting of (in mM):  NaCl (115), KCl (5), CaCl2 (2.5), MgCl2 (1.3), dextrose 
(23), sucrose (26), HEPES (4.2), and pH = 7.2 (Stellwagen and Malenka, 2006).  
On the day of the experiment, the osmolarity of the media from the cultures was 
measured (normally 285 – 295 mOsm) and the perfusate osmolarity was 
adjusted to match the culture osmolarity to guard against osmotic shock to the 
neurons.  To isolate glutamatergic mEPSCs, TTX (500 nM) and picrotoxin (50 
μM) were included in the perfusion solution to block action potentials and 
GABAergic currents, respectively.  Patch electrodes (3.5 – 5 MΩ) were filled with 
an internal solution containing (in mM):  K-gluconate (128), NaCl (10), EGTA (1), 
CaCl2 (0.132), MgCl2 (2), HEPES (10), and pH = 7.2.  Osmolarity was adjusted to 
10 mOsm less than the perfusion solution osmolarity.  Neurons were clamped at 
a voltage of -60 mV using an Axopatch 200B patch-clamp (Axon Instruments) 
and recorded from for 2 – 5 minutes.  Data were collected with Clampex 10.0 
(Axon Instruments). 
 
Data Analysis of mEPSCs 
 Mini Anaysis software (Synaptosoft) was used to identify mEPSCs and all 
events above a threshold of 3 pA were included in the data.  We obtained a 
mean mEPSC amplitude for each neuron and, unless otherwise noted, n is the 
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number of neurons .  All data were pooled based on the experimental condition 
from 2-10 separate cultures.  Overall means for each condition were determined 
from the pooled data and are presented as ±SEM for the number of neurons 
indicated.  mEPSC data were compared using an unpaired Student’s t-test and 
statistical significance established at p < 0.05.   
 For cumulative probability distribution plots of mEPSC amplitude, the first 
50 mEPSCs were selected per cell per experimental condition, pooled together, 
and sorted in ascending order.  Experimental mEPSC amplitude distributions 
were plotted on the same graph as control mEPSC amplitude distributions for 
comparisons of shifts in distributions.              
 
mEPSC Recordings are AMPAergic 
 To determine that all events in our recordings of mEPSCs from neurons 
were AMPAergic in nature and to eliminate the possibility of contamination of our 
data with NMDA-mediated mEPSCs, we performed whole-cell voltage clamp on 
wild-type control neurons in the presence of the AMPA receptor blocker, CNQX 
(10 μM).  The experiment was done as follows; dissociated cultures of mixed glial 
and neuronal populations from Rab3A+/+ mouse cortex were set up as described 
above, were not chronically treated with TTX, and were recorded from at 13 DIV.  
Baseline neuronal activity was determined by whole-cell voltage clamp, as 
described above, for 2 minutes and were performed in the presence of TTX (500 
nM, to block action potentials) and picrotoxin (50 μM, to block GABAA –mediated 
currents) to isolate mEPSCs.  After the 2 minute baseline recordings, the AMPA 
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receptor blocker, CNQX (10 μM), was perfused into the recording chamber for 2 
minutes to allow for its action.  Once the CNQX was washed in for 5 minutes, 
mEPSCs were recorded for 5 minutes, followed by a 10 minute wash-out of 
CNQX, and then recorded from again to get a post-CNQX recording.  This was 
done on 2 separate cultures for a total of 5 cells.  
 Here we show that all mEPSCs we recorded are AMPAergic.  When 
mEPSCs were recorded in the presence of CNQX, all activity was silenced 
(Figure 6, middle), and activity was re-established upon removal of the AMPAR 
block (Figure 6, bottom).  The same result was observed in 5 out of 5 cells.               
 
 
III.  SPECIFIC AIMS 
 
Three Specific Aims were tested to elucidate the role of Rab3A in regulating 
homeostatic synaptic plasticity: 
1. Complete loss (Rab3A-/-) and mutation of Rab3A (Rab3Aebd/ebd) eliminates 
the homeostatic increase in synaptic strength in dissociated mouse 
cortical neuron cultures. 
2. GluR2-containing AMPA receptors, not GluR1, are increased after chronic 
TTX blockade, and ablation of Rab3A prevents this increase. 
3. Neuronal Rab3A, not glial Rab3A, is responsible for regulating the 
homeostatic increase in mEPSC amplitude. 
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Specific Aim 1:  Complete loss (Rab3A-/-) or mutation of Rab3A 
(Rab3Aebd/ebd) eliminates the homeostatic increase in synaptic strength in 
dissociated mouse cortical neuron cultures. 
 
Rationale 
 As mentioned earlier, the presynaptic GTPase, Rab3A, has been 
implicated in several forms of synaptic plasticity in the nervous system (Castillo 
et al., 1997; Thakker-Varia et al., 2001; Wang et al., 2011).  Our lab has recently 
demonstrated that normally functioning Rab3A is necessary for homeostatic 
synaptic plasticity at the mouse neuromuscular junction (NMJ) and that complete 
loss of Rab3A results in a blunted homeostatic response to chronic activity 
silencing via TTX (Wang et al., 2011).  Additionally, the homeostatic increase in 
synaptic strength observed at the mouse NMJ is not accompanied by an 
increase surface expression of postsynaptic receptors (Wang et al., 2011) as has 
been observed in many studies of homeostatic plasticity at central synapses 
(Table 1).  Taken together, the lack of change in postsynaptic receptor 
expression, and that the requirement for a presynaptic protein, Rab3A, in 
homeostatically-induced increases in synaptic strength at the mouse NMJ, 
suggest that there may be a presynaptic mechanism involved in the regulation of 
the activity-dependent increase in miniature endplate currents (mEPCs).  One 
study has provided evidence for presynaptic modulation of miniature inhibitory 
postsynaptic currents (mIPSCs) in a homeostatic manner.  In conjunction with 
everything discussed thus far involving excitatory synaptic homeostasis, 
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chronically blocking synaptic activity also triggers a decrease in the amount of 
inhibition by reducing mIPSC amplitude.  This has been shown to be 
accompanied by a reduction in the amount of postsynaptic GABAA receptors in 
neocortical synapses (Kilman et al., 2002), and by also decreasing presynaptic 
vesicle filling of GABA via the reduction of the GABA biosynthetic enzyme 
glutamic acid decarboxylase (GAD65) and the vesicular GABA transporter 
(VGAT) in hippocampal synapses (Hartman et al., 2006).  No presynaptic 
regulatory role or molecule has been established for the homeostatic regulation 
of excitatory synapses.  Since our lab has previously shown that the Rab3Aebd/ebd 
mutant impairs homeostatic synaptic plasticity at the mouse NMJ, we 
hypothesized that normally functioning Rab3A is required for the homeostatic 
increase in synaptic strength at central synapses. 
 
Protocol 
 To test our hypothesis, we used whole-cell voltage clamp to record 
mEPSCs from cortical pyramidal neurons in control and TTX-treated sister 
cultures.  Culture, electrophysiology, and data analysis were performed as 
described earlier in the Materials and Methods section.  TTX effects on cortical 
pyramidal neuron mEPSC characteristics were examined on cultures prepared 
from Rab3Aebd/ebd mice and compared to cultures prepared from wild-type mice in 
that colony; the same comparison was performed on cultures prepared from 
Rab3A-/- cortical pyramidal neurons and cultures prepared from wild-type mice in 
the same colony.  Rab3Aebd/ebd and Rab3A-/- mice were maintained through 
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distinct, non-overlapping breeding colonies.  Statistical significance was 
determined as p < 0.05. 
 
Results 
 To test the effect of chronic inactivity and the role of the Rab3A ebd 
mutation on the physiological properties of excitatory synapses, we measured 
the amplitude and frequency of mEPSCs from TTX-treated (48 hours) and 
untreated sister cultures of Rab3Aebd/ebd dissociated cortical pyramidal neurons 
and compared these to wild-type (Rab3A+/+) cultures.  Untreated Rab3A+/+ 
neurons had an average amplitude of 11.0 ± 0.6 pA and occurred at a frequency 
of 1.15 ± 0.19 Hz (n = 20 cells).  The amplitude of mEPSCs was significantly 
increased with chronic silencing of synaptic activity by TTX in Rab3A+/+ neurons 
(15.1 ± 1.2, n = 23 cells, p = .007 compared to control; Figure 7A left panel, C 
left, and D), and the TTX effect was blocked in Rab3Aebd/ebd cultures (untreated, 
14.9 ± 1.0 pA vs. TTX-treated 14.6 ± 1.1 pA, p = 0.86.  Control n = 22 cells, TTX 
n = 22; Figure 7A right panel, C right, and D).  We did observe that the control 
mEPSC amplitude of Rab3Aebd/ebd cultures was increased (14.9 pA) when 
compared to the control amplitude of Rab3A+/+ cultures (11.0 pA) and that this 
increase resembled the amplitude of TTX-treated Rab3A+/+ cultures (15.1 pA) 
(Figure 7D).  We cannot rule out that the ebd mutation itself produces a TTX-like 
effect on mEPSC amplitude that obscures the actual TTX-induction of increasing 
amplitude by achieving maximal synaptic efficacy without TTX, and a similar 
increase was observed at the NMJ (Wang et al., 2011).  However, this may also 
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be due to culture-to-culture variations in mEPSC amplitude because other labs 
have shown high variability of mEPSC amplitudes across cultures (Cingolani and 
Goda, 2008; Gainey et al., 2009; Stellwagen and Malenka, 2006), and we have 
also seen this high variability in mEPSC amplitudes in our experiments.  
Although it is possible that there exist a threshold where basal amplitude is too 
large that it is no longer able to produce a homeostatic increase, we have data 
and results from our pooled Rab3A+/+ cultures (Rab3A KO colony) that show TTX 
treatment is able to increase mEPSC amplitude to 18.2 pA (Figure 8D); this 
allows us to believe that the lack of effect of TTX to reflect true inhibition of the 
homeostatic plasticity mechanism.   
The mEPSC frequency of neurons from Rab3A+/+ mice also increased 
significantly with chronic TTX treatment (untreated, 1.15 ± 0.19 Hz vs. TTX-
treated, 2.54 ± 0.55 Hz.  Untreated n = 20, TTX-treated n = 23, p = 0.030; Figure 
7A left and B), which was blunted in Rab3Aebd/ebd neurons (untreated, 1.64 ± 0.39 
Hz vs. TTX-treated, 3.05 ± 0.80 Hz, p = 0.12.  Untreated n = 22 neurons, TTX n = 
22 neurons; Figure 7A right panel and B).  These results demonstrate that 
normally functioning Rab3A is essential for the homeostatic increase in mEPSC 
amplitude and frequency.   
 We next wanted to determine the effect of complete loss of Rab3A 
(Rab3A-/-) on the homeostatic changes on mEPSC physiological characteristics. 
To test this, we performed the same experiments as done on Rab3Aebd/ebd 
neurons, but using cortical cultures from Rab3A-/- mice and their wild-type 
counterparts.  Untreated neurons from Rab3A+/+ exhibited a significant increase 
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in both mEPSC amplitude and frequency when compared to sister cultures that 
were chronically silenced for 2 days by TTX (14.0 ± 0.7 pA vs. 18.2 ± 0.8 pA, P = 
0.0004, and 2.03 ± Hz vs. 4.14 ± 0.67 Hz, P = .005, respectively.  Untreated n = 
26, TTX n = 20; Figure 8).  When the same experiments were performed on 
Rab3A-/- neurons, the TTX-induced increase in mEPSC amplitude was blocked 
(13.5 ± 0.8 pA vs. 14.3 ± 0.7 pA, P = 0.5, control n = 22, TTX n = 21; Figure 7A, 
C, and D).  Ablation of Rab3A also blunted the homeostatic increase in mEPSC 
frequency (2.94 ± 0.54Hz vs 3.70 ± 1.13 Hz, P = 0.5, control n = 22, TTX n = 21; 
Figure 7A and B).  These results strongly suggest that Rab3A is necessary for 
the physiological expression of increased synaptic strength as a result of chronic 
TTX induced homeostatic synaptic plasticity in mouse cortical neurons. 
  
Discussion 
 Chronic perturbations in the synaptic activity of neuronal networks are 
known to cause global compensatory changes in synaptic strength between 
neurons.  Our findings here demonstrate the essential role of a presynaptic 
protein, Rab3A, in regulating the homeostatic increase in synaptic strength at 
AMPAergic synapses.  Our data demonstrate that either a mutation to obstruct 
Rab3A’s GTPase activity or complete loss of the protein inhibits the homeostatic 
increase in mEPSC amplitude and blunts the response on mEPSC frequency in 
dissociated mouse cortical pyramidal neurons.     
It is well-established that chronic silencing of neuronal networks leads to 
an increase in mEPSC amplitude and several molecules have been identified to 
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support the mechanism of homeostatic postsynaptic modulation of glutamatergic 
AMPA receptors, including glial release of the pro-inflammatory cytokine, TNFα, 
which increases expression of surface AMPARs (Beattie et al., 2002), up-
regulation of all-trans retinoic acid (RA) synthesis to increase surface GluR1-
containing AMPA receptors (Aoto et al., 2008) and the requirement of Fragile X 
mental retardation protein (FMRP) in the RA-dependent upregulation of GluR1 
AMPARs (Soden and Chen, 2010), loss of Arc, an immediate-early gene 
associated with information encoding in the brain, results in increased basal 
GluR1 surface expression and mEPSC amplitude and prevents the TTX-induced 
increase in amplitude (Shepherd et al., 2006), and β3-integrin, a cell adhesion 
molecule involved in the endocytosis of AMPARs, is necessary for the 
homeostatic increase in cell membrane GluR2-containing AMPA receptor 
numbers (Cingolani et al., 2008). 
As mentioned previously, glial release of factors in response to chronic 
activity deprivation have also been shown to be important for increasing synaptic 
strength by increasing the amount of postsynaptic GluR1-containing AMPA 
receptors.  To this date, no known presynaptic mechanism or molecules have 
been shown to be involved in the homeostatic increase in synaptic strength, but 
our discovery that Rab3A is necessary for this process provides a novel 
physiological role for Rab3A at central synapses and could provide the first 
evidence of a presynaptic mechanism in homeostatic synaptic plasticity. 
 There are several potential Rab3A-dependent mechanisms for regulating 
the increase in synaptic strength in neurons (Figure 9).  Rab3A could work 
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presynaptically by increasing the amount of glutamate loaded into synaptic 
vesicles in response to chronic activity silencing, as has been seen with GABA in 
inhibitory neurotransmission (Hartman et al., 2006).  The increase in the amount 
of transmitter being released per vesicle would subsequently activate more 
postsynaptic AMPA receptors causing an increase in mEPSC amplitude.  
Another potential Rab3A-dependent mechanism is that Rab3A homeostatically 
controls the release of a presynaptic signaling molecule that travels across the 
synaptic cleft to activate the increased insertion of postsynaptic AMPARs, 
resulting in increased synaptic strength.  A third potential mechanism for Rab3A 
in homeostatic synaptic plasticity located in the postsynaptic cell could be that 
Rab3A, known to be involved in the trafficking of vesicles, acts from its location 
within the postsynaptic neuron by shuttling AMPAR-loaded vesicles to the 
synapse when neuronal activity is deprived, allowing for increased synaptic 
strength.  The last mechanism whereby Rab3A could regulate the homeostatic 
increase in synaptic strength is that Rab3A in glia, in response to persistent 
activity suppression, modulates the release of a glial-derived factor, such as 
TNFα, that signals to increase postsynaptic expression of AMPARs.   
Due to the fact that malfunctioning of neuronal activity homeostasis has 
been implicated in neurological and psychiatric diseases, determining Rab3A’s 
role in regulating the enhancement of synaptic efficacy in this process would 
provide a better understanding of this mechanism and molecular signals.  This 
better understanding could provide for new drug targets and therapies.  As a first 
step, we address whether loss of Rab3A prevents increased neurotransmitter 
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loading in synaptic vesicles or increased postsynaptic AMPA receptors in 
Specific Aim 2. 
 
Specific Aim 2:  Rab3A-/- blocks the homeostatic increase in postsynaptic 
expression of surface GluR2-containing AMPA receptors in response to 
chronic activity blockade. 
 
 Specific Aim 2 was designed to determine the role of Rab3A in the 
mechanism of homeostatic synaptic plasticity.  As mentioned previously, there 
are several possibilities for the site of Rab3A’s mechanism of action in response 
to chronic activity deprivation, such as: 1. acting presynaptically to alter synaptic 
vesicle neurotransmitter concentration, 2. regulating the presynaptic release of a 
molecule that signals to the postsynaptic neuron to increase AMPAR numbers, 3. 
working in the postsynaptic neuron to control the increased trafficking of AMPA 
receptors to the synapse, or 4. modulating the release of a glial-derived factor 
that subsequently signals to increase AMPAR numbers in the postsynaptic 
neuron.  The scope of this Aim was to determine if Rab3A is involved in a 
presynaptic mechanism by assessing the amount of transmitter loaded into 
synaptic vesicles by using a glutamate competitive antagonist or if it is required 
to induce the necessary postsynaptic manipulations to AMPAR numbers, and 
more specifically, which AMPAR subunit, GluR1 or GluR2, it may be regulating.  
We have partitioned Specific Aim 2 into 3 subsections to answer these questions:  
A. Presynaptic Mechanism:  Neurotransmitter Concentration, B. Postsynaptic 
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Mechanism:  GluR1-containing AMPARs, and C. Postsynaptic Mechanism:  
GluR2-containing AMPARs.          
 
A. Presynaptic Mechanism: Neurotransmitter Concentration 
 
Is Rab3A mediating a presynaptic homeostatic mechanism?  Links between 
presynaptic homeostasis, BNDF, and Rab3A. 
 Our results demonstrating that the synaptic vesicle protein, Rab3A, is 
necessary for the expression of increased synaptic strength in homeostatic 
synaptic plasticity could lead to the first line of evidence of a presynaptic 
mechanism and the identification of a presynaptic molecule linked to the process 
of homeostatically increasing excitatory synaptic strength.  As mentioned earlier, 
homeostatic modulation of neurotransmitter concentration has been shown in 
inhibitory synaptic transmission in hippocampal neurons.  Chronic activity 
blockade via TTX triggers a decrease in mIPSC amplitude due to TTX-induced 
downregulation of the GABA synthesizing enzymes, glutamic acid decarboxylase 
67 (GAD67) (Lau and Murthy, 2012) and GAD65 (Hartman et al., 2006), and 
decreased vesicle loading of GABA has been demonstrated by increased 
sensitivity to a competitive GABA antagonist (Hartman et al., 2006).  This TTX-
driven homeostatic decrease in inhibitory synaptic transmission is also regulated 
by brain-derived neurotrophic factor (BDNF) via TrkB receptor signaling as 
demonstrated by the prevention of the activity deprivation effects on GABAergic 
synapses when cultures were co-treated with BDNF (Swanwick et al., 2006).  
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BDNF application to hippocampal neurons has been shown to increase Rab3A 
protein expression and to potentiate synaptic activity; the BDNF-induced 
potentiation of synaptic activity is abolished in neurons lacking Rab3A (Thakker-
Varia et al., 2001).  These data illustrate BDNF’s role in modulating synaptic 
activity in decreasing inhibitory synaptic transmission by reducing GABA 
concentration in synaptic vesicles resulting in increased excitatory synaptic 
transmission and increased synaptic strength.  The fact that BDNF signaling is 
able to 1.) vary the amount of the inhibitory transmitter, GABA, loaded into 
vesicles in an activity-dependent manner, 2.) that Rab3A is required for a BDNF-
driven potentiation of excitatory synaptic activity, and 3.) that no evidence to date 
has implicated a homeostatic mechanism at excitatory synapses of modulation of 
glutamate concentration in vesicles makes it reasonable to believe that BDNF 
may be signaling through Rab3A to regulate the amount of glutamate loaded into 
vesicles at excitatory synapses.   
 
Is Rab3A mediating a presynaptic homeostatic mechanism?  The role of Rab3A 
in fusion pore kinetics. 
Another possibility for Rab3A to modulate the amount of neurotransmitter 
present in the synaptic cleft is by regulating synaptic vesicle exocytotic fusion 
pore kinetics.  Fusion pores are channels that form at the initial phase of 
exocytosis sometimes resulting in full-collapse vesicle fusion and release of all 
transmitter content of that vesicle, or, failure to achieve full fusion and releasing 
varying amounts of transmitter into the synaptic cleft (Ales et al., 1999).  In 
34 
 
adrenal chromaffin cells, loss of Rab3A results in abnormally slow-rising and long 
duration pre-spike feet of amperometric events, corresponding to fusion of single 
catecholamine-containing vesicles (Wang et al., 2008).  As pre-spike feet are a 
measure of fusion pore dynamics (Wightman et al., 1995), this result suggests 
Rab3A may regulate the amount of transmitter available in the cleft in a fusion 
pore-dependent manner. 
 
Can a change in glutamate release result in a different mEPSC amplitude?   
Variations in glutamate concentration in the synaptic cleft have been 
shown to be the primary source of variability in evoked EPSC amplitude.  It has 
also been concluded that vesicular packets of transmitter are not able to saturate 
postsynaptic receptors (Liu et al., 1999), leaving room for fluctuations in 
glutamate concentration as a source of variability in mEPSC amplitudes (Wu et 
al., 2007), leaving the possibility for these fluctuations in vesicular glutamate 
content to contribute to a presynaptic mechanism in homeostatic plasticity.   
Since Rab3A localizes to synaptic boutons and associates with vesicles, is 
necessary for BDNF-induced synaptic plasticity, exhibits the ability to regulate 
fusion pore kinetics, and we have now shown its requirement for the expression 
of homeostatic plasticity, we hypothesized that Rab3A is required for a 
homeostatic increase in the amount of neurotransmitter released into the 
synaptic cleft. 
 
Protocol 
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 To test our hypothesis that Rab3A is homeostatically regulating the 
amount of transmitter released into the synaptic cleft, we used the compound, γ-
D-glutamylglycine (γ-DGG), to investigate this possibility.  γ-DGG is a glutamate 
receptor antagonist that has a low affinity for AMPA receptors (Watkins et al., 
1990) and is a rapidly dissociating competitive antagonist of glutamate (Liu et al., 
1999), allowing for the investigation of cleft glutamate concentrations.  If 
variations in mEPSC amplitude are due to variations in the amount of glutamate 
in the cleft, there should be an inverse correlation in the amount of γ-DGG 
inhibition and the size of mEPSC amplitude.  In other words, if large amplitude 
mEPSCs are due to increased glutamate concentration, then these larger 
amplitude mEPSCs would show decreased sensitivity to γ-DGG because the 
increased glutamate in the synaptic cleft would out-compete γ-DGG for AMPA 
receptor binding, and vice versa.   
We used whole-cell voltage clamp to record mEPSCs from untreated and 
TTX-treated (48 hours) sister cultures of Rab3A+/+ (Rab3A colony) neurons 
before and after γ-DGG application.  Cultures were prepared as described in the 
Materials and Methods section.  Electrophysiology was performed as described 
earlier, except basal recordings were done for 4 minutes, followed by a 2 minute 
wash-in with γ-DGG (500 μM) added to perfusate, and then a 4 minute recording 
from the same neuron in the presence of γ-DGG.  This was done on untreated 
and TTX-treated sister cultures of Rab3A+/+ neurons and results compared 
between the 2 experimental conditions.   
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Neuronal mEPSC data were analyzed as described in the Materials and 
Methods section.  Mean percent reduction of mEPSC amplitudes for each cell in 
untreated and TTX-treated conditions in response to γ-DGG were calculated, 
then pooled together for each condition to obtain an overall mean percent 
reduction for untreated and TTX-treated conditions, and were compared.  
Statistical significance was established as p < 0.05.  Also, each individual 
neuron’s percent reduction was plotted against its basal average mEPSC 
amplitude to determine whether any relationships exist between initial amplitude 
or TTX treatment and the amount of reduction on mEPSC amplitude observed 
with γ-DGG inhibition.   
 
Results 
 When we compared the average amount of reduction on mEPSC 
amplitudes of control and TTX-treated neurons triggered by competitive 
antagonism via γ-DGG, we found there was no difference between the two 
conditions (26.1 ± 3.4% reduction in control vs. 26.6 ± 4.8% in TTX-treated, p = 
0.9.  Control n = 12, TTX n = 9; Figure 10A.).  This could be due to the lack of a 
strong TTX effect on mEPSC amplitude as a result of control neuron’s exhibiting 
a large basal mean amplitude prior to γ-DGG application (16.2 ± 1.0 pA vs. 18.4 
± 1.4 pA, p = 0.21, control n = 12, TTX n = 9, data not shown).  This could 
obscure any differences we may have seen in the amount of γ-DGG inhibition 
because the initial amplitudes of control and TTX-treated neurons were very 
similar.  To address this, we then examined each cell individually to determine if 
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large amplitude neurons were less sensitive to γ-DGG inhibition and if small 
amplitude cells were more sensitive to γ-DGG, and whether this was dependent 
on TTX-treatment.  We discovered that the percent reduction on mEPSC 
amplitude was independent of initial amplitude size or of a TTX effect (Figure 
10B) as we observed individual neurons which had small mEPSC amplitudes 
and were relatively insensitive to γ-DGG (Figure 10B and C, top, note, the 
smallest amplitudes were all from untreated cultures), an untreated neuron with a 
large mEPSC amplitude was highly sensitive to γ-DGG (Figure 10B and C, 
middle), and a TTX-treated neuron with a large mEPSC amplitude was highly 
sensitive (Figure 10B and C, bottom).  These surprising results that larger 
amplitudes are more sensitive to γ-DGG is opposite of what would be expected if 
large mEPSC amplitude was a result of increased neurotransmitter.  This 
strongly suggests that the amount of γ-DGG inhibition is irrespective of mEPSC 
amplitude or chronic TTX treatment. 
 
Discussion 
 Our surprising results that γ-DGG was less effective in inhibiting small 
amplitudes and had varying effects on mEPSC inhibition regardless of mEPSC 
size or TTX effect (Figure 10B and C) strongly suggests that sensitivity to γ-DGG 
is independent of amplitude and chronic network silencing.  This is the opposite 
result expected if variations in mEPSC amplitude were due to transmitter 
concentration.  If transmitter concentration was equivalent in small and large 
amplitude cells, we would expect to see the same amount of reduction of 
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mEPSC amplitudes of untreated and TTX-treated neurons.  Instead, our results 
indicate that, 1.) very large amplitude must be due to increased receptors and not 
transmitter concentration, and, 2.) when increased receptors are present they 
may serve as a sink for glutamate, lowering its concentration in the synaptic cleft 
and making the neuron more sensitive to γ-DGG.   
These results are strong evidence that presynaptic modulation of 
neurotransmitter is not the mechanism for homeostatic increases in mEPSC 
amplitude in the face of chronic network silencing.  They also strongly suggest 
that neurotransmitter concentration within synaptic vesicles is widely varying, 
potentially contributing to the high variability seen in mEPSC amplitudes.  Also, 
neurons with large mean amplitudes actually appear to be contacted by 
presynaptic neurons that have, on average, vesicles with less neurotransmitter 
content because some of the largest amplitude cells exhibited the most 
sensitivity to competitive antagonism by γ-DGG (Figure 10B).  This heightened 
sensitivity to γ-DGG in large amplitude neurons may also provide evidence for an 
increase in postsynaptic AMPA receptors, which has been well-established to 
contribute to activity-dependent increases in mEPSC amplitude.  Our results 
presented here argue against an involvement of a presynaptic mechanism 
modulating an increase in neurotransmitter concentration to enhance synaptic 
efficacy in response to chronic activity deprivation, and may point towards the 
postsynaptic mechanism of modulating AMPA receptors and Rab3A’s 
involvement in regulating their activity-dependent increase.   
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B.  Postsynaptic Mechanism:  GluR1-containing AMPA Receptors 
 
Rationale 
 Bidirectional AMPA receptor trafficking via vesicles to and from the 
synapse has been well documented and occurs in an experience-dependent 
manner to influence synaptic strength (Heynen et al., 2000; Takahashi et al., 
2003), and during homeostatic synaptic plasticity (Wierenga et al., 2005).  
Knockout of the GluR1 subunit impairs the regulation of synaptic strength and 
distance-dependent synaptic scaling in the CA1 region of the mouse 
hippocampus  (Andrasfalvy et al., 2003). Since AMPA receptors are known to be 
shuttled to and from the cell surface and Rab3A has long been known as a small 
GTPase that cycles between association and dissociation with GTP and synaptic 
vesicles (Fischer von Mollard et al., 1990) to traffic vesicular cargo for exocytosis 
(Matteoli et al., 1991), it is reasonable to believe that Rab3A could also be 
involved in the postsynaptic transport of AMPA receptor-loaded vesicles.     
 As mentioned previously, modifications to postsynaptic AMPA receptor 
levels are now known to play an essential role for the expression of homeostatic 
synaptic plasticity, but there is disagreement between the involvement of the 
GluR1 subunit or the GluR2 subunit.  Several studies have demonstrated the 
increased insertion of GluR1-containing AMPA receptors in response to chronic 
activity blockade (Table 1).  Another study showed that BDNF contributes to the 
bidirectional cell surface expression of both GluR1-containing AMPA receptors 
and GluR2-containing AMPA receptors in nucleus accumbens medium spiny 
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neurons (Reimers et al., 2014), and 2 other studies, 1 on nucleus accumbens 
neurons (Sun and Wolf, 2009) and the other on visual cortical cultures (Wierenga 
et al., 2005), also showed that prolonged activity silencing increases cell surface 
expression of both GluR1 and GluR2.  Preferential homeostatic upregulation of 
GluR2-containing AMPA receptors has also been shown (Cingolani et al., 2008) 
and the GluR2 subunit has been demonstrated to be required for synaptic 
scaling, a type of homeostatic plasticity (Gainey et al., 2009).  Despite the 
discrepancy in which AMPA receptor subunit is responsible for the expression of 
homeostatic plasticity, the majority of evidence supports the upregulation of the 
GluR1 subunit after prolonged activity deprivation (Table 1).         
Based on our results here demonstrating Rab3A’s requirement for the 
expression of increased mEPCS amplitude in homeostatic synaptic plasticity 
(Figure 7 and 8) and that increased transmitter concentration does not account 
for this increase in amplitude (Figure 10), we hypothesized that Rab3A is 
regulating the increase in synaptic efficacy in response to chronic activity 
silencing by modulating the increase in postsynaptic AMPA receptors, specifically 
the GluR1 subtype since overwhelming evidence has shown the homeostatic 
increase in GluR1 expression.   Although we know of no postsynaptic 
involvement of Rab3A in the trafficking vesicles to the membrane, it is 
reasonable to believe that Rab3A could be involved in this process due to its 
already known role in trafficking synaptic vesicles for exocytosis and in the 
secretory pathway.  The fact that BDNF-induced plasticity is reliant on Rab3A 
and BDNF has recently been shown to adjust surface AMPA receptor levels in a 
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homeostatic manner, allows for the possibility that Rab3A is affecting 
postsynaptic AMPA receptor expression in an activity-dependent manner to 
increase synaptic strength, or provides a link between Rab3A and receptor 
trafficking.  A potential role for Rab3A to modulate receptor trafficking could be by 
regulating the release of a neuronal factor, such as BDNF, which in turn 
regulates receptors postsynaptically.  To our knowledge, this would provide a 
novel role for Rab3A and the first evidence of its postsynaptic function.  
 
Protocol 
 Here, we tested whether GluR1 is increased homeostatically using 2 
approaches: 1.) immunohistochemistry of surface GluR1 expression, and 2.) a 
selective GluR1 antagonist, NASPM (a synthetic analog of Joro spider toxin).  
We examined GluR1 receptor levels in untreated and TTX-treated (2 days) sister 
cultures, and some of these cultures we also measured mEPSC amplitudes to 
establish a physiological correlate with the staining for GluR1 expression.  
NASPM experiments were performed on untreated and TTX-treated (2 days) 
sister cultures and all recordings were done before and after NASPM.  
 
Immunohistochemistry.   
 Primary cultures of wild-type mouse cortical neurons and TTX treatment 
were prepared as described in the Materials and Methods section.  Surface 
expression of GluR1 was examined on 2 week old cultures of untreated and 
TTX-treated sister cultures of wild-type pyramidal neurons.  Antibody to GluR1 
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(see Table 2 for information regarding antibodies) was added to unfixed 
coverslips in the culture media in which each coverslip was grown (so not to 
introduce any changes in osmolarity or factors released by glia and neurons that 
coverslips have been exposed to while in culture), 5% donkey serum.  Coverslips 
were incubated for 45 minutes in a 37°C, 5% CO2 incubator.  Neurons were then 
rinsed with PBS, fixed for 10 minutes in 4% paraformaldehyde at room 
temperature, rinsed with PBS, and then rinsed with donkey serum, and incubated 
1 hour at room temperature with Cy5 (649) donkey anti-rabbit secondary 
antibody (Jackson Immunoresearch) in 5% donkey serum.  The cells were then 
permeabilized with 0.2% saponin before incubating in MAP2 and VGLUT1 
antibodies, to label cell bodies and dendrites, and presynaptic glutamatergic 
terminals, respectively.  Cells were then incubated in secondary antibodies for 45 
minutes, rinsed, and then mounted to slides using VectaShield mounting medium 
(Vector Labs) to reduce photobleaching.  Slides were stored at 4°C and imaged 
within a few days by confocal microscopy.   
 Confocal images were acquired on an Olympus FV1000 confocal 
microscope using FluoView 2.1 software.  The objective was 60X (oil immersion), 
with a numerical aperture of 1.35.  A single image of a visually identified 
pyramidal neuron was acquired before applying a 5X zoom to acquire a stack of 
images of the primary dendrite (section thickness = 0.5 microns).  Where 
possible, ten cells and their primary dendrites were imaged per coverslip per 
treatment condition (untreated and TTX-treated).  Imaging parameters of PMT 
and laser percent were adjusted for each laser to maximize brightness without 
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causing saturation.  The same parameters were used for untreated and TTX-
treated coverslips from a single experiment. 
 
Image Analysis   
The confocal z-stack of the dendrite was flattened using Image Pro 6 
(Cybernetics), and an area of interest (AOI) defined that included the dendrite 
plus a fixed amount outside the dendrite (to capture receptor clusters on spines) 
that was defined by using the process command morphological filter to “swell” 
the dendrite.  To quantify the size, intensity, and integrated intensity of receptor 
clusters, a threshold was set (400-600 depending on overall brightness; the 
same threshold was used for untreated and TTX-treated in a single experiment)  
and the count command applied to automatically circle receptor clusters that 
were located within the AOI.  To exclude multiple clusters that had been circled 
as a single cluster due to their proximity, clusters larger than 0.8 microns (check 
by looking at several dendrites and finding out what is the biggest size) were not 
included in the analysis.  Cluster area, intensity, and integrated intensity were 
acquired, and the average across the clusters determined for each dendrite, and 
then an overall average across dendrites were calculated.  The effect of TTX was 
assessed in 2 ways.  For the total number of 7 experiments, the untreated and 
TTX-treated means for each experiment were compared with a student’s t-Test, 
where n = number of experiments.  For 2 experiments in which physiology was 
performed on the same day as immunohistochemistry, data are presented as 
individual experiments.  
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Synaptic Analysis  
In ImagePro 6, dendrite (color 1), VGLUT1-positive presynaptic terminal 
(color 2) and receptor antibody-positve clusters (color 3) are visible 
simultaneously in the composite image, facilitating identification of synaptic pairs 
that are located on or close to the dendrite.  To find a synaptic pair, the slice 
number is cycled up and down the confocal stack, and coexisting pre- and 
postsynaptic sites circled by hand to create the AOIs. The stack number for each 
AOI is noted for use later. When all of the synaptic pairs for an individual dendrite 
have been circled, the AOI list is saved. Next, the single color image for 
receptors is viewed, each AOI is placed on the image, on the correct confocal 
slice, and the count tool is used to automatically circle the receptor cluster. The 
measurement values (area, intensity, and sum) are copied to an Origin file, with 
all of the data for a single dendrite accumulated in one worksheet, for calculating 
an average for the dendrite.  
 
Physiological Blockade of GluR1-mediated mEPSCs by NASPM 
N-naphthyl acetylspermine (NASPM) is a selective antagonist of GluR2-
lacking AMPA receptors (Koike et al., 1997).  It has been shown to abolish 
homeostatic induced increases in mEPSC amplitudes induced in chick  
motoneurons in vivo  by activity blockade via the sodium channel blocker, 
lidocaine, for 2 days (Garcia-Bereguiain et al., 2013), which suggests that in that 
preparation GluR2-lacking AMPA receptors are entirely responsible for the 
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activity-deprivation induced increase in mEPSC amplitude.  Cultures were 
prepared and whole-cell voltage clamp was performed as described in the 
Materials and Methods section.  Baseline recordings were performed for 2 
minutes and the same patched cell was then perfused with a high K+ solution 
containing NASPM (same solution used for baseline recordings except [KCl] = 25 
mM, [NaCl] = 95 mM, and NASPM = 20 μM) for 45 seconds.  NASPM is an 
activity-dependent drug, so perfusion with the high K+ solution caused the cell to 
depolarize, inducing a high frequency of evoked synaptic events (personal 
observation) which allows glutamate binding to open GluR2-lacking AMPA 
receptors.  After 45 seconds, perfusion was returned to our normal extracellular 
solution used for the basal recordings, but with NASPM (20 μM) and the cell was 
allowed to recover its membrane potential to resting levels.  After 5 minutes, a 5 
minute recording of mEPSCs was then acquired in the presence of NASPM.  For 
each cell, there was a baseline recording and a NASPM recording.   
Mean pre-NASPM recordings for each cell in each condition (untreated vs. 
TTX-treated) were pooled together to acquire an overall mean amplitude and 
frequency for untreated and TTX-treated conditions.  These were then compared 
to determine a TTX effect on mEPSC amplitude and frequency.  NASPM’s effect 
on mEPSC amplitude and frequency was determined by comparing the different 
conditions, untreated vs. TTX-treated, before and after NASPM.  TTX effects on 
mEPSC characteristics was established by an unpaired Student’s t-test 
comparing overall means of untreated and TTX-treated pre-NASPM recordings, 
and NASPM’s effect on each neuron’s mEPSC amplitude and frequency was 
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compared before and after NASPM  using a paired sample t-test. Statistical 
significance was determined as p < 0.05.  In addition, we calculated the mean 
amplitude for the largest 25 events from each neuron recorded from and plotted 
the percent change in amplitude after NASPM against the pre-NASPM amplitude 
for each individual neuron.   
 
Results  
 
Effect of activity blockade on GluR1 receptor levels: immunohistochemistry 
We stained untreated and TTX-treated Rab3A+/+ cultures for GluR1 to 
determine if the homeostatic increase in mEPSC amplitude seen with chronic 
activity silencing is accompanied by an increase in cell surface expression of 
GluR1-containing AMPA receptors.  Example images of GluR1 expression in 
untreated and TTX-treated cultures are shown in Figure 11 (these images are 
only intended to demonstrate immunohistochemistry of MAP2, VGLUT1, and 
GluR1 expression; not to show any differences between untreated and TTX-
treated conditions).  We found that overall total size of GluR1 puncta did not 
change between control and TTX-treated sister cultures of Rab3A+/+ pyramidal 
neurons (0.32 ± 0.06 μm2 vs. 0.31 ± 0.05 μm2, paired t-Test p = 0.9, n = 7 
cultures; Figure 12A, left).  There was also no difference GluR1 cluster intensity 
in untreated and TTX-treated Rab3A+/+ cultures (untreated, 988 ± 51 arbitrary 
units (a.u.) vs. 991 ± 56 a.u., paired t-Test p = 0.8, n = 7 cultures; Figure 12B, 
left).  When we analyzed individual experiments, we found a variable effect of 
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chronic TTX silencing on GluR1 size in Rab3A+/+; out of 7 cultures, 2 showed a 
dramatic increase in GluR1 puncta size (60% and 78%; Figure 12A, right), 1 
showed a decrease (-53%, Figure 12A, right), and 4 showed very modest 
changes (12%, -10%, -14%, and -16%; Figure 12A, right).  Analysis of individual 
experiments on surface GluR1 intensity showed there were essentially little to no 
change in intensity (Figure 12B, right).  These results left us with the questions of 
whether there are multiple mechanisms involved in the expression of 
homeostatic synaptic plasticity as has been suggested by the disagreement over 
GluR1 or GluR2 involvement (see Table 1, addressed in Specific Aim 2C), or, 
sometimes there is not a TTX effect on mEPSC amplitude (addressed below). 
Because we have seen some individual wild-type cultures that have not 
exhibited a measurable physiological increase in mEPSC amplitude after TTX 
blockade, and the differences in GluR1 immunohistochemistry from experiment 
to experiment varied widely (Figure 12A, right), we examined GluR1 
immunohistochemistry in 2 cultures for which we also performed 
electrophysiological measurements on the same day.  Recordings were taken 
from neurons in untreated and TTX-treated cultures and coverslips from the 
same cultures were subjected to immunohistochemistry for surface GluR1 
expression; this would allow us to determine a correlation between a 
physiological TTX-induced increase in mEPSC amplitude and cell surface GluR1 
expression.  To our knowledge, recordings of mEPSCs from the same cultures 
that are used investigate AMPA receptor expression by immunohistochemistry 
have never been done before.  For imaging and GluR1 immunohistochemistry 
48 
 
analysis, we presented all dendrites imaged from each of the 2 experiments 
along with the mean across dendrites for each experiment.  We also added an 
analysis of synaptically identified GluR1 clusters, selected by their proximity to 
presynaptic VGLUT1. 
In the first physiology-GluR1 immunohistochemistry correlation experiment 
(Experiment 1), we observed an increase in mEPSC amplitude after chronic TTX 
treatment, that did not reach significance (untreated, 13.8 ± 2.2 pA vs. TTX-
treated, 17.7 ± 1.8 pA, p = 0.19.  Untreated n = 7, TTX treated n = 8 neurons; 
Figure 13A).  Because the TTX effect is of small magnitude, the number of cells 
needed to observe a statistically significant effect is usually >8, which is why we 
perform multiple days of recordings.  Despite this caveat, Experiment 1 showed a 
strong trend towards a TTX-induced increase in mEPSC amplitude that we felt 
would be accompanied by at least a trend toward increased surface GluR1 
expression after chronic TTX-treatment if GluR1 were the AMPA receptor subunit 
responsible for the homeostatic increase in mEPSC amplitude.  The results were 
clear; there was no change in total GluR1 puncta size after chronic silencing 
(untreated, 0.28 ± 0.02 μm2 vs. TTX-treated, 0.27 ± 0.02 μm2, p = 0.87.  
Untreated n = 10, TTX-treated n = 9; Figure 13B, left) or in total GluR1 intensity 
(untreated, 741 ± 19 a.u. vs. 738 ± 5 a.u., p = 0.86.  Untreated n = 10, TTX-
treated n = 9; Figure 13B, right), and the same result was seen with synaptic 
GluR1 cluster size (untreated, 0.15 ± 0.02 μm2 vs. TTX-treated, 0.17 ± 0.02 μm2, 
p = 0.44.  Untreated n = 10, TTX-treated n = 10; Figure 13C, left) and synaptic 
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GluR1 intensity (untreated, 657 ± 22 μm2 vs. TTX-treated, 663 ± 17 μm2, p = 
0.83.  Untreated n = 10, TTX-treated n = 10; Figure 13C, right).   
The second time we performed the physiology-GluR1 
immunohistochemistry experiment (Experiment 2), we had a strong TTX-induced 
increase in mEPSC amplitude (untreated, 13.5 ± 1.5 pA vs. TTX-treated, 19.1 ± 
1.8 pA, p = 0.034.  Untreated n = 7, TTX-treated n = 6; Figure 14A).  Because of 
the strong TTX effect on mEPSC amplitude in Experiment 2, we would expect a 
very clear increase in GluR1 expression if GluR1 upregulation were mediating 
the homeostatic increase mEPSC amplitude.  Again, the results were clear; 
surface GluR1 expression in Experiment 2 did not increase (puncta size:  
untreated, 0.27 ± 0.04 μm2 vs. TTX-treated, 0.22 ± 0.01 μm2, p = 0.18; Figure 
14B, left.  Intensity:  untreated, 761 ± 17 a.u. vs. TTX-treated, 750 ± 8 μm2, p = 
0.58; Figure 14B, right.  Untreated n = 10, TTX-treated n = 10).  There were also 
no homeostatic changes in synaptic GluR1 expression (puncta size:  untreated, 
0.13 ± 0.01 μm2 vs. 0.13 ± 0.02 μm2, p = 0.83; Figure 14C, left.  Intensity:  615 ± 
13 a.u. vs. 631 ± 17 a.u., p = 0.45; Figure 14C, right.  Untreated n = 10, TTX-
treated n = 10).   
In summary, when physiology-GluR1 expression correlation experiments 
were performed, we found no evidence of an increase in GluR1 levels, despite 
there being a clear demonstration of a TTX-induced increase in mEPSC 
amplitude in the same experiment.  These results suggest that either GluR1 is 
not involved in the homeostatic response to chronic activity deprivation, which is 
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unlikely due to the prevalence of studies showing GluR1 increased 
homeostatically, or there multiple homeostatic mechanisms exist. 
We also performed immunohistochemistry experiments for GluR1 
expression in response to chronic TTX treatment in Rab3A-/- cultures.  
Interestingly, there was a modest homeostatic increase in GluR1 levels despite 
the loss of Rab3A (untreated, 0.30 ± 0.03 μm2 vs. TTX-treated, 0.33 ± 0.03 μm2, 
p = 0.40, n = 7 cultures; Figure 15A), and analysis of individual cultures revealed 
that 2 out of 4 experiments demonstrated the modest homeostatic increase in 
GluR1 puncta size (Figure 15B).  These data from Rab3A-/-, like the 
immunohistochemistry experiments examining homeostatic changes in GluR1 
levels in wild-type cultures, again show that a subset of cultures show a modest 
homeostatic increase in GluR1 expression, and that loss of Rab3A does not 
prevent this increase.        
     
Effect of activity blockade on GluR1 levels: selective antagonism by NASPM 
Because immunohistochemistry experiments revealed no changes in 
GluR1 levels after chronic TTX-treatment even when a homeostatic increase in 
mEPSC was observed (Figures 13 and 14), it is possible that 
immunohistochemistry was not sensitive enough, that our methods of analysis 
failed to pick up a genuine change, or multiple mechanisms can increase 
mEPSC amplitude in a homeostatic manner.  Since several other studies have 
shown increased GluR1 levels after chronic activity silencing (Table 1), we used 
another independent measure that should reveal if there were a significant 
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increase in GluR1 homomers, a selective antagonist of GluR2-lacking receptors 
that has previously been used to demonstrate a selective contribution of GluR2-
lacking receptors to a homeostatic increase in synaptic strength in chick spinal 
cord neurons (Garcia-Bereguiain et al., 2013).  If the increase in synaptic 
strength after chronic activity-deprivation is due to increased expression of GluR1 
homomeric receptors, we would expect NASPM application to abolish the 
increase in mEPSC amplitudes in TTX-treated neurons.  The most striking effect 
of NASPM we found was on mEPSC frequency.  We were surprised to find that 
the homeostatic increase in mEPSC frequency (untreated pre-NASPM, 1.88 ± 
0.41 Hz vs. TTX-treated pre-NASPM, 4.23 ± 0.90 Hz, untreated n = 16 neurons, 
TTX n = 13 neurons, p = 0.017; Figure 16C) was abolished after NASPM 
(untreated pre-NASPM, 1.88 ± 0.41Hz vs. TTX-treated NASPM, 2.40 ± 0.61, 
untreated n = 16 neurons, TTX n = 13 neurons, p = 0.47; Figure 16C).  Paired 
analysis before and after NASPM for both untreated and TTX-treated conditions 
showed significant decreases in mEPSC frequency in response to NASPM 
inhibition, although the effect was more pronounced in TTX-treated cultures 
(untreated: pre-NASPM, 1.88 ± 0.41 Hz vs. NASPM, 1.46 ± 0.36 Hz, n = 16, p = 
0.027; Figure 16C, black bars.  TTX-treated: pre-NASPM, 4.23 ± 0.90 Hz vs. 
NASPM, 2.40 ± 0.61 Hz, n = 13, p = 0.006; Figure 16C, green bars, and E). 
Our result showing that NASPM inhibition of GluR1 AMPA receptors 
blocks the homeostatic increase in frequency is highlighted in an individual 
neuron from a TTX-treated culture in Figure 16.  Figure 16D shows a portion of a 
recording before and after NASPM where the frequency was decreased by 
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43.4%, but there was no effect of NASPM on decreasing that same cell’s 
mEPSC amplitude (pre-NASPM, 18.6 pA vs. NASPM, 18.9 pA; Figure 16B, right 
- the histogram plot in Figure 16B labeled “Neuron 2” is from the same cell as the 
example trace in Figure 16D).  If GluR1-containing AMPA receptors were solely 
responsible for the homeostatic increase in amplitude, we would have expected 
this cell, which exhibited a TTX-induced increase in mean amplitude (18.6 pA), to 
have a mean amplitude after NASPM (18.9 pA) that resembled the mean 
amplitude of untreated cultures (~ 13 pA).  Our findings that inhibition of GluR1-
containing AMPA receptors via NASPM has varying effects on blocking the TTX-
induced increase in mEPSC amplitude but does block the homeostatic increase 
in frequency, suggests that postsynaptic patches of AMPA receptors are not 
heterogeneous mixtures of different receptor subunits, but rather are exclusively 
regions of either GluR1-containing or GluR2-containing receptors.  To our 
knowledge, this is a novel finding.           
Whole-cell voltage clamp of pyramidal neurons from Rab3A+/+ cultures 
showed an increase in mEPSC amplitude in response to chronic TTX-treatment 
when pre-NASPM recordings from untreated and TTX-treated (48 hours) were 
compared (untreated, 13.1 ± 0.9 pA vs. TTX, 16.6 ± 1.0 pA, p = 0.016, 26.7% 
increase in amplitude.  Untreated n = 16 cells, TTX-treated n = 13 cells; Figure 
16A).  However, NASPM treatment did not affect the TTX-induced increase in 
amplitude (untreated to TTX-treated % increase after NASPM = 26.6%), and they 
did not resemble untreated, pre-NASPM recordings as would be expected if the 
homeostatic increase in mEPSC amplitude were due to increased GluR1 
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expression (untreated pre-NASPM, 13.1 ± 0.9 pA vs. TTX NASPM, 15.7 ± 0.9 
pA, p = 0.06.  Untreated pre-NASPM n = 16, TTX-treated NASPM n = 13; Figure 
16A, CON pre bar vs. TTX NASPM bar).   
These results are unlikely to be due to a lack of effect of NASPM because 
paired analysis of individual neurons showed very slight, but not significant, 
reductions in mEPSC amplitude after NASPM (untreated pre-NASPM 13.1 ± 0.9 
pA vs. untreated NASPM 12.4 ± 0.7 pA, p = 0.29, n = 16; Figure 16A, black bars.  
TTX-treated pre-NASPM 16.6 ± 1.0 pA vs. TTX-treated NASPM 15.7 ± 0.9 pA, n 
= 13, p = 0.18; Figure 16A, green bars).  In addition, we observed a clear and 
consistent effect of NASPM on frequency, regardless of its effect on amplitude 
(Figure 16C) 
Further examination of the amplitude histograms in cells in which NASPM 
caused a reduction in amplitude, suggests that NASPM may be mainly acting on 
the largest amplitude events (Figure 16B, Neuron 1, compare pre and post 
NASPM). To examine whether NASPM had a differential effect on the largest 
amplitude events, we determined the mean of the top 25 events, before and after 
NASPM, and calculated a percent change. While there was not a significant 
difference in magnitude of NASPM effect in untreated and TTX-treated cells, 
when we plotted the percent change as a function of the pre-NASPM mean of the 
largest 25 events in each cell, there was a weak (R2 = 0.19) but significant (p = 
0.01) relationship, with the cells that had the largest “top 25” means having the 
largest decreases with NASPM. Since the cells with the largest “top 25” means 
are TTX-treated cells, this result suggests there is some contribution, albeit 
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small, of Glur2-lacking receptors to the TTX-induced increase in mEPSC 
amplitude in our cultures.  
    
Discussion 
Our evidence of neurons with larger events trending to towards increased 
NASPM sensitivity, coupled with the result that 2 out of 7 of the GluR1 
immunohistochemistry experiments on wild-type cultures and 2 out of 4 
experiments on Rab3A-/- cultures showed a homeostatic increase in GluR1 
expression, points toward some involvement of GluR1 in homeostatic plasticity 
that is not Rab3A-dependent in our cultures, but clearly cannot fully explain the 
homeostatic increase in mEPSC amplitude.  Based on these data using 2 
independent approaches, immunohistochemistry and pharmacology, we 
demonstrate that the TTX-induced increase in mEPSC amplitude in our 
preparation is not due to a selective increase GluR1 receptor expression.  It was 
very surprising to us that NASPM did block the homeostatic increase in 
frequency, a novel finding suggesting homogeneity of receptor type expression in 
individual receptor patches.       
     
C. Postsynaptic Mechanism:  GluR2-containing AMPA Receptors 
 
Rationale 
 Since our thorough approach using 2 independent methods of 
immunohistochemistry and pharmacology did not expose a strong role for GluR1 
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in the homeostatic increase in mEPSC amplitude (Specific Aim 2B), we wanted 
to test whether an increase in GluR2-containing AMPA receptor number was 
responsible for the increase in synaptic strength in our cultures, and if Rab3A 
was involved in this process.  Although evidence predominantly has implicated 
GluR1 upregulation as the source for the homeostatic increase in mEPSC 
amplitude, other labs have shown that GluR2 is responsible for the increase in 
mEPSC amplitude after chronic network silencing (Table 1).   
  
Protocol 
 Cultures, physiology, and immunohistochemistry experiments were 
performed as described in Specific Aim 2B, with the exception that GluR2 
immunohistochemistry analysis looked at synaptic GluR2 expression only due to 
the extreme amount of GluR2 expression that made it impossible to ensure that 
individual clusters could be automatically circled across the whole dendrite in a 
flattened image.  In some immunohistochemistry experiments had 
electrophysiology performed on the same day.  Physiology statistics were 
performed as described in the Materials and Methods section and 
immunohistochemistry statistics were performed as outlined in Specific Aim 2.  
 
Results 
 We performed immunohistochemistry on untreated and TTX-treated sister 
cultures of Rab3A+/+ and Rab3A-/- cortical pyramidal neurons to test if GluR2 
expression is upregulated with chronic activity deprivation and whether loss of 
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Rab3A affects GluR2 expression patterns.  Example images of GluR2 
immunohistochemistry are in Figure 17 (these are simply for demonstration of 
synaptic sites, and not intended to show any TTX-induced changes in GluR2 
expression).  Chronic TTX treatment produced a modest increase in synaptic 
GluR2 cluster size in pyramidal neurons from Rab3A+/+ cultures (untreated, 0.83 
± 0.08 μm2 vs. TTX-treated, 0.97 ± 0.10 μm2, p = 0.18 (paired t-Test).  Untreated 
n = 5,TTX-treated n = 5; Figure 18A, left), and this modest effect on GluR2 
expression was blocked in Rab3A-/- cultures (untreated, 0.75 ± 0.17 μm2 vs. TTX-
treated, 0.74 ± 0.07 μm2, p = 0.94 (paired t-Test).  Untreated n = 4, TTX-treated n 
= 4; Figure 18C, left).  As we observed with GluR1 expression after chronic TTX 
treatment (Figure 12), homeostatic changes in GluR2 expression also had 
experiment to experiment variation (Figure 18A, right, and 18C, right), although 
to a lesser degree than GluR1.  Interestingly, 4 out of 5 experiments on Rab3A+/+ 
cultures showed a homeostatic increase in synaptic GluR2 puncta size while the 
other experiment showed a decrease in GluR2 puncta size (Figure 18A, right), 
and 3 out of 4 experiments on Rab3A-/- cultures exhibited a decrease after TTX 
while the other experiment showed a dramatic increase GluR2 expression 
(Figure 18C, right).  GluR2 intensity did not change in response to TTX treatment 
either in Rab3A+/+ cultures (untreated, 731 ± 38 a.u. vs. TTX-treated, 735 ± 27 
a.u., p = 0.77 (paired t-Test).  Untreated n = 5, TTX-treated n = 5; Figure 18B) or 
in Rab3A-/- cultures (untreated, 715 ± 38 a.u. vs. TTX-treated, 735 ± 14 a.u., p = 
0.64 (paired t-Test).  Untreated n = 4, TTX-treated n = 4; Figure 18D).   
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Although these results suggest Rab3A may have some involvement in the 
homeostatic upregulation of GluR2-containing AMPA receptors, the 2 
experiments that had the opposite expected effects on changes in GluR2 
expression after TTX was puzzling.  In some of these experiments, we also 
performed electrophysiology, so we wanted to determine, as we did with GluR1, 
if there was a correlation between a homeostatic increase in mEPSC that was 
accompanied by an increase in GluR2 expression in the same culture.  Of the 5 
Rab3A+/+ cultures we performed GluR2 immunohistochemistry on, we also 
recorded mEPSCs in 3 experiments.  In Experiment 1 (Rab3A+/+), a homeostatic 
increase in mEPSC amplitude (28.3%) was observed (not significant, p = 0.19; 
Figure 19A) and was accompanied by a 47.5% increase in synaptic GluR2 
puncta size (not significant, p = 0.13; Figure 19B, left).  Experiment 2 (Rab3A+/+) 
also showed a correlation between a TTX-induced increase in mEPSC amplitude 
(12.0%, not significant, p = 0.58; Figure 19C) and increased synaptic GluR2 
expression after chronic silencing (20.6%, not significant, p = 0.25; Figure 19D, 
left).  (Note: the modest size of the homeostatic effect is such that we do not 
expect individual experiments with these n’s to reach significance).  The fact that 
the modest increase in amplitude observed in Experiment 2 (Rab3A+/+) was 
accompanied by a similarly modest increase in GluR2 expression, and that the 
large homeostatic increase in mEPSC amplitude seen in Experiment 1 
(Rab3A+/+) was accompanied by a large increase in GluR2 expression in 
suggests that in these 2 cultures GluR2 upregulation is responsible for the 
homeostatic increase in mEPSC amplitude. 
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The third physiology-GluR2 immunohistochemistry experiment on 
Rab3A+/+ cultures (Rab3A+/+, Experiment 3) produced a surprising result where a 
17.2% homeostatic increase in amplitude (not significant, p = 0.09; Figure19E) 
was accompanied by a 9.2% decrease in synaptic GluR2 puncta size (not 
significant, p = 0.58; Figure 19F, left).  Another study has also shown that a 
homeostatic decrease in GluR2-containing AMPA receptors after chronic activity 
deprivation results in increased mEPSC conductance which is mediated by a 
resulting increase in the proportion of GluR1 homomers (Garcia-Bereguiain et al., 
2013), which are reported to have a larger conductance than GluR1-GluR2 
(Swanson et al., 1997).  Such a shift from heteromers to GluR1 homomers could 
possibly explain why a modest homeostatic increase in mEPSC amplitude might 
be accompanied by an decrease in GluR2.   
Physiology-GluR2 immunohistochemistry correlation experiments were 
also performed on cortical cultures from Rab3A-/- mice to test whether loss of 
Rab3A affects the homeostatic expression of GluR2 AMPA receptors.  In 
Experiment 1 (Rab3A-/-), we saw a slight increase in mEPSC amplitude with 
chronic TTX treatment (11.4%, not significant, p = 0.53; Figure 19G) that was 
accompanied by a very large increase in GluR2 puncta size (146.8%, p = 0.0002; 
Figure 19H, left).  It is puzzling that this very large homeostatic increase in GluR2 
expression (146.8%) was not accompanied by a correlative very large increase in 
mEPSC amplitude (11.4%), but large homeostatic increases in GluR2 expression 
(>140%) have been reported by other labs (Sun and Wolf, 2009; Wierenga et al., 
2005).  Also, it must be noted that in Experiment 1 (Rab3-/-) the untreated GluR2 
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puncta size is much smaller (Figure 19H, left) than any of the other GluR2 
immunohistochemistry experiments examining puncta size, leaving us with the 
question of whether there truly was a very large increase in synaptic GluR2 
puncta size or if this increase was exaggerated due to the unexplained low 
GluR2 expression in the untreated condition.   
Experiments 2 and 3 from Rab3A-/- cultures produced similar results to 
each other where the loss of Rab3A not only blocked the homeostatic increase in 
mEPSC amplitude, but also caused it to decrease slightly (Experiment 2:  -6.5%, 
Figure 19I, left; Experiment 3:  -11.2%, Figure 19K, left), and the decreases in 
amplitude  were accompanied by correlative decreases in synaptic GluR2 puncta 
size (Experiment 2:  -7.2%, Figure 19J, left; Experiment 3:  -11.3%, Figure 19L, 
left).  The results from Experiments 2 and 3 on Rab3A-/- cultures suggest that in 
these two cultures that the loss of Rab3A blocked the homeostatic increase in 
GluR2 expression resulting in the inhibition of the homeostatic increase in 
mEPSC amplitude.     
 
Discussion 
 Our results examining the role of GluR2 expression in response to chronic 
network silencing showed that in some cultures GluR2 levels are homeostatically 
increased and that the loss of Rab3A appears to block their increase which 
results in the inhibition of the homeostatic response on mEPSC amplitude.  
However, in Experiment 3 on Rab3A+/+ cultures (Figure 19E and F), where a 
homeostatic increase in mEPSC amplitude was accompanied by a decrease in 
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GluR2 expression, strongly suggests that multiple mechanisms may be involved 
in the expression of homeostatic synaptic plasticity, as has been suggested by 
others (Garcia-Bereguiain et al., 2013) (see also Table 1).  
 
Specific Aim 3:  Neuronal Rab3A, not glial Rab3A, is responsible for 
regulating the homeostatic increase in mEPSC amplitude. 
 
Rationale 
 We have shown in Specific Aim 1 that Rab3A is essential for the 
homeostatic increase in synaptic strength (Figures 7 and 8).  As mentioned 
earlier, several possibilities exist as to the location of where Rab3A may be 
acting to exert its regulatory action to increase mEPSC amplitude in a 
homeostatic manner (Figure 9).  
Mounting evidence suggests that glial-neuronal interactions are complex 
and important for normal nervous system function (Haydon, 2001).  As 
mentioned earlier, glia have been shown to be important for enhancing excitatory 
neurotransmission by releasing factors such as glypican-4 and TNFα to increase 
synaptic strength, and TNFα has been demonstrated to be essential for 
homeostatic synaptic plasticity.  Both of these molecules produce their effect by 
increasing cell surface expressionof GluR1-containing AMPA receptors (Allen et 
al., 2012; Stellwagen and Malenka, 2006).  Since Rab3A is expressed in glia 
(Madison et al., 1996), it is reasonable to believe that glial Rab3A may mediate 
the release of activity-dependent factors, such as TNFα, from glia in response to 
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activity deprivation, that signal to increase AMPA receptor insertion into the 
postsynaptic membrane.  The scope of Specific Aim 3 was to determine whether 
neuronal or glial Rab3A was modulating the homeostatic increase in synaptic 
strength. 
 
Protocol 
 To test our hypothesis that glial Rab3A is necessary for the increase in 
synaptic strength in homeostatic synaptic plasticity, we cultured Rab3A+/+ 
neurons onto Rab3A-/- or Rab3A+/+ glial feeder layers, and Rab3A-/- neurons onto 
Rab3A+/+ glia (Figure 20A).    
 
Preparation of Glial Feeder Layers 
 Glial feeder layers were prepared from the cortices of P0-P2 Rab3A+/+ or 
Rab3A-/- mouse pups.  Cortices were dissected and cells were dissociated as 
described previously in the Materials and Methods section.  Cell suspensions of 
mixed neuronal and glial populations were plated onto glass coverslips pre-
coated with poly-L-lysine (Corning) in Dulbecco’s Modified Eagle Media (Life 
Technologies, Invitrogen) supplemented with 5% FBS (to promote glial 
proliferation and to kill neurons), L-glutamine, and gentamicin, and maintained in 
an incubator at 37°C, 5% CO2; cultures were maintained in this manner for up to 
1 month until seeded with neurons.  Culture media was replaced after 24 hours, 
and subsequent media changes were made twice weekly replacing half of the 
culture media with fresh media.  Feeder layers were not used for neuronal 
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seeding until all native neurons were gone and glial cells approached 100% 
confluency (visually inspected). 
 
Plating of Neurons on Glial Feeder Layers 
 Cortical neurons were obtained as described in the Materials and Methods 
section.  Upon acquisition of a pellet containing mixed neuronal and glial 
populations, the pellet was resuspended in Neurobasal-A (270 mOsm) containing 
B27 (2%, to promote neuronal growth), L-glutamine, and 5-fluorodeoxyuridine 
(FdU, a mitotic inhibitor).  Addition of FdU was used to prevent glial growth and 
contamination of the glial feeder layer with new glia, promoting only neuronal 
growth on the feeder layers (this media was used for the maintenance of these 
cultures and all subsequent media changes were with this media).  Glial culture 
media was removed from the feeder layer cultures, and the cell suspension was 
plated onto the glial feeder cultures.  Culture strategy is outlined in Figure 15A.  
At 1 DIV all of the culture media was removed and replaced with fresh 
Neurobasal-A media described above, and half of the media was replaced twice 
per week for all subsequent media changes.  Cultures were maintained in a 
37°C, 5% CO2 incubator for 13-14 days.   
 
Electrophysiology 
 TTX treatment of cultures, whole-cell voltage clamp, data acquisition, data 
analysis, and statistics of mEPSCs from cortical pyramidal neurons were 
performed as described in the Materials and Methods section.  
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Results 
 To test whether glial Rab3A was responsible for the homeostatic increase 
in synaptic strength, we cultured wild-type neurons onto Rab3A-/- glial feeder 
layers and recorded mEPSCs from untreated cultures and TTX-treated (48 
hours) sister cultures and compared mEPSC amplitude and frequency between 
the two conditions.  We first performed these experiments on cultures of wild-
type neurons on wild-type glial feeder layers to demonstrate that this new 
culturing strategy of glial feeder layers exhibited a homeostatic increase in 
mEPSC amplitude (untreated, 13.3 ± 0.5 pA vs. TTX-treated, 16.7 ± 1.2 pA, p = 
0.022.  Untreated n = 17, TTX-treated n = 20; Figure 20B, left and middle).  
Despite not being significant, these cultures trended towards a homeostatic 
increase in frequency (untreated, 2.54 ± 0.57 Hz vs. TTX-treated, 3.48 ± 0.64 Hz, 
p = 0.29.  Figure 20B, right) – (mEPSC data from Specific Aim 1 showing initial 
results of a homeostatic increase in synaptic strength in our original culturing 
strategy of wild-type neurons are provided in Figure 20C for reference).  
Rab3A+/+ neurons plated on Rab3A-/- glia still showed a robust homeostatic 
response on mEPSC amplitude (untreated, 13.3 ± 1.0 pA vs. TTX-treated, 18.8 ± 
1.4 pA, p = 0.005.  Untreated n = 11, TTX-treated n = 11; Figure 20D, left and 
middle), and trended towards a homeostatic increase in frequency (untreated, 
2.01 ± 0.41 Hz vs. TTX-treated, 4.47 ± 1.53 Hz, p = 0.14; Figure 20D, right).  This 
result indicates that Rab3A is not required in the glia.  We also performed the 
same experiment on cultures of Rab3A-/- neurons on wild-type glia, and the 
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homeostatic response was reduced and no longer significant (untreated, 15.2 ± 
1.1 pA vs. TTX-treated, 16.9 ± 0.7 pA, p = 0.23.  Untreated n = 14, TTX-treated n 
= 11; Figure 20E, left and middle), but there was a slight decrease in mEPSC 
frequency that was not significant (untreated, 4.47 ± 1.21 Hz vs. 3.02 ± 0.70 Hz, 
p = 0.35; Figure 20E, right) – (mEPSC data from Specific Aim 1 showing initial 
results of loss of Rab3A blocking the homeostatic increase in synaptic strength in 
our original culturing strategy are provided in Figure 20F for reference).  These 
results further confirm that Rab3A localized within neurons is playing a key role in 
regulating homeostatic synaptic plasticity.   
   
Discussion 
 These results, that loss of glial Rab3A does not block the homeostatic 
increase in mEPSC amplitude, and loss of neuronal Rab3A does block the TTX-
induced increase in amplitude, focuses the potential possibilities for Rab3A-
dependent homeostatic increases in mEPSC amplitude to two possible 
mechanisms.  The first possibility is that Rab3A is working in the presynaptic 
neuron, not to modulate transmitter content within synaptic vesicles as we 
originally postulated (see Specific Aim 2A, and Figure 10), but rather by 
regulating the anterograde signaling of the presynaptic release of neurotrophic 
factors that travel across the synaptic cleft that subsequently signal to increase 
AMPA receptor levels in the postsynaptic membrane (Figure 9, #2).  The second 
possibility is that Rab3A is located in the postsynaptic neuron and is involved in 
increasing the trafficking of AMPA receptors for insertion into the postsynaptic 
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membrane in response to chronic activity deprivation (Figure 9, #3).  Both of 
these possibilities would provide new insight and better understanding of the 
homeostatic mechanism for increasing mEPSC amplitude.  To our knowledge, 
there is currently no evidence for anterograde signaling from the presynaptic to 
the postsynaptic neuron to homeostatically increase AMPA receptor numbers, 
and despite Rab3A’s known role in vesicle trafficking, the predominant belief is 
that its action is in the presynaptic neuron and not the postsynaptic neuron.  If 
Rab3A were located within the postsynaptic neuron and regulated AMPA 
receptor insertion, it would provide a novel physiological role for Rab3A in the 
postsynaptic neuron as well as establishing a new molecule involved in the 
homeostatic upregulation of AMPA receptor levels.             
 
IV.  DISSERTATION SUMMARY 
 
Specific Aim Conclusions 
Specific Aim 1 
1. Loss of Rab3A blocks the homeostatic increase in synaptic strength. 
2. Mutation of Rab3A blocks the homeostatic increase in synaptic strength. 
 
Specific Aim 2 
A.  Presynaptic Mechanism – Transmitter Concentration 
1. γ-DGG sensitivity is independent of mEPSC amplitude and of TTX effect. 
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2. Neurons with large mean amplitudes appear to have less neurotransmitter 
or more receptors because the neuron with the largest mean amplitude 
was the most sensitive to γ-DGG. 
3. Neurotransmitter concentration varies widely within vesicles. 
 
B.  Postsynaptic Mechanism – GluR1-containing AMPA Receptors 
1. NASPM inhibition of the homeostatic increase in mEPSC frequency 
suggests that postsynaptic patches of receptors may not be 
heterogeneous, but rather exclusively GluR1 or GluR2-containing. 
2. GluR1-containing AMPA receptors have some involvement in the 
homeostatic increase in mEPSC amplitude. 
3. The TTX-induced increase in mEPSC amplitude in our preparation is not 
due to a selective increase GluR1 receptor expression. 
4. Loss of Rab3A does not prevent a modest homeostatic increase in GluR1 
levels.   
5. Multiple mechanisms may exist in the manifestation of the homeostatic 
increase in mEPSC amplitude. 
 
C.  Postsynaptic Mechanism – GluR2-containing AMPA receptors 
1. The homeostatic increase in GluR2 expression appears more consistently 
than an increase in GluR1, but GluR2 involvement cannot fully explain the 
homeostatic increase in mEPSC amplitude. 
2. Loss of Rab3A may block the homeostatic increase in GluR2 levels. 
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3. Multiple mechanisms may exist for the manifestation of homeostatic 
increase in mEPSC amplitude. 
 
Specific Aim 3 
1. Loss of glial Rab3A does not block the homeostatic increase in mEPSC 
amplitude. 
2. Loss of neuronal Rab3A does block the homeostatic increase in mEPSC 
amplitude. 
 
Homeostatic synaptic plasticity provides synaptic circuits with the ability to 
maintain stable functioning when faced with destabilizing perturbations in 
synaptic activity that may arise from other plasticity mechanisms, such as LTP 
and LTD.  Since the discovery of homeostatic plasticity in 1998, much effort has 
been devoted to exposing the mechanism underlying the nervous system’s ability 
to compensate for chronic perturbations in synaptic activity.  Consistent in many 
studies is that the compensatory increase in synaptic strength in response to 
chronic network silencing is accompanied by an increase in postsynaptic AMPA 
receptors, but discrepancies exist as to whether GluR1 or GluR2 levels are 
changed (see Table 1).  Based on our findings presented here, we believe that 
multiple mechanisms exist and no single mechanism can explain the 
manifestation of the homeostatic change in synaptic strength.  For example, in 
our experiments we cannot conclude a selective regulation of GluR1 or GluR2 
because both appear to contribute.  Despite our evidence suggesting there is not 
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a selective homeostatic increase in GluR1 vs. GluR2-containing AMPA 
receptors, we have strongly demonstrated that the loss or the mutation of Rab3A 
prevents the homeostatic increase in synaptic strength.   
In Specific Aim 1 we definitively demonstrated that Rab3A is essential for the 
manifestation of the homeostatic increase in mEPSC amplitude and that the 
location of Rab3A’s action in homeostatic plasticity is in the neuron and not in the 
glia (Specific Aim 3).  When we attempted to determine the mechanism of  
homeostatic plasticity so that we could then determine if loss of Rab3A disrupted 
that mechanism, we ruled out a presynaptic mechanism (Specific Aim 2A) and 
focused on postsynaptic modulation of AMPA receptors, specifically GluR1 and 
GluR2-containing AMPA receptors (Specific Aim 2B and C), as substantial 
evidence suggests an upregulation of AMPA receptors in response to chronic 
network activity silencing (Table 1).   
Initially we did not see an overall homeostatic increase in GluR1 expression, 
but when we examined individual experiments for GluR1 involvement, we could 
not rule out some involvement of GluR1-containing AMPA receptors because we 
observed a small subset of cultures that did exhibit a homeostatic increase in 
GluR1 expression (Figure 12A, right), and this modest homeostatic increase in 
GluR1 levels was not prevented with loss of Rab3A.  Electrophysiological 
experiments with pharmacological blockade of GluR1-containing AMPA 
receptors via NASPM further confirmed that there is a weak involvement of 
GluR1 receptors in increasing mEPSC amplitude as neurons with the largest “top 
25” mean trended towards increased NASPM-sensitivity (Figure 16D).   
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Since upregulation of GluR1 receptors after chronic TTX treatment seemed 
to have only a minor homeostatic role in our cultures, we tested whether GluR2-
containing AMPA receptor levels were increased after chronic activity silencing.  
We discovered that GluR2 expression increased modestly with TTX-treatment 
(Figure 18A) and that this modest increase in GluR2 expression was blocked in 
Rab3A-/- cultures (Figure 18C).  Despite the homeostatic increase in GluR2 
expression being slight, we feel it correlates with our physiology data because 
homeostatic increases in mEPSC amplitude are also small in magnitude.  When 
physiology was coupled with GluR2 immunohistochemistry experiments to 
determine whether a correlation exists between increased mEPSC amplitude and 
increased GluR2 expression and if Rab3A is involved, we found that 2 out of 3 
Rab3A+/+ cultures and 1 Rab3A-/- culture demonstrated a relationship between a 
homeostatic increase in amplitude and GluR2 expression (Figure 19A, B, C, and 
D), and that the other 2 experiments on Rab3A-/- cultures blocked both the 
homeostatic increase in amplitude and GluR2 levels (Figure 19I, J, K, and L).  
The Rab3A-/- culture that exhibited both an increase in amplitude and GluR2 
expression could be attributed to falling within the realm of an experimental 
variability that is large in comparison to homeostatic changes that are small in 
magnitude.  In the Rab3A+/+ culture that showed a slight homeostatic increase in 
amplitude despite a slight decrease in GluR2 expression (Figure 19E and F), we 
believe this may hint at another mechanism of homeostatic plasticity as 
suggested by another lab where a decrease in GluR2-containing AMPA 
receptors shifts the ratio in favor of GluR1 receptors resulting in increased 
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conductance that subsequently increase mEPSC amplitude (Garcia-Bereguiain 
et al., 2013).   
With all things considered, our data and the data previously published are 
consistent with the presence of multiple mechanisms that can accomplish 
homeostatic synaptic plasticity.  This would explain the divergence in the field 
about GluR1 vs. GluR2 involvement in homeostatic plasticity, and 2 studies have 
shown that both GluR1 and GluR2 are homeostatically upregulated proportionally 
(Table 1).  Another possibility for the variability in finding GluR1 or GluR2 
involvement in homeostatic plasticity, is that there could exist 2 phases, as 
suggested for LTP (Plant et al., 2006), where the early initiation phase of the 
homeostatic mechanism could involve insertion of GluR1 receptors, which are 
eventually replaced by incorporation of GluR2 receptors into the membrane for 
the maintenance of homeostatic plasticity.  This could also explain why we did 
not always see a homeostatic increase in GluR2 expression and saw an increase 
in GluR1 levels in a small subset of experiments.  Protocols for activity blockade 
in previous studies range from 24 hours to 72 hours with the majority of studies 
using a 24 hour or 48 hour block of activity (Table 1).  The majority of those 
experiments that used a 24 hour block to induce homeostatic plasticity observed 
increased GluR1 expression, while most of the studies that showed a 
homeostatic increase in GluR2 receptors blocked network activity for 48 hours 
(Table 1).  In our experiments, we blocked network activity via TTX treatment of 
cultures for 2 days, and if there are phasic roles for GluR1 and GluR2 in the 
initiation and maintenance of homeostatic plasticity, respectively, it may explain 
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why we saw a more consistent homeostatic increase in GluR2 expression since 
we performed our experiments during what would be the phase of GluR2 
involvement.  The 2 experiments where we saw increased GluR1 expression, or 
the experiment where GluR2 did not increase, could be due to biological 
variability around when the initiation phase segues into the maintenance phase.   
Our results show that both GluR1 and GluR2 can increase in response to 
chronic activity deprivation, but which predominates appears to vary from culture 
to culture, and possibly, from cell to cell.  In our preparation, a homeostatic 
increase in GluR2 was more consistent, and with the exception of a strange 
outlier with an unusually low level of GluR2 expression in the untreated culture 
(Figure 18G and H), loss of Rab3A prevented the TTX-induced upregulation of 
GluR2 receptors, but not GluR1 receptors.  Based on our results that GluR1 and 
GluR2 are both likely contributing to the manifestation of homeostatic synaptic 
plasticity, that loss of Rab3A appears to prevent the homeostatic increase in 
GluR2 but not GluR1receptors, and evidence of a biphasic mechanism in LTP 
involving GluR1 and GluR2 AMPA receptors (Plant et al., 2006), we believe that 
homeostatic plasticity occurs through a biphasic mechanism that is Rab3A-
dependent.  We propose a model (Figure 21) that a chronic decrease in network 
activity induces (Phase 1, ~ day 1) the homeostatic response by triggering glial 
release of TNFα that signals to the postsynaptic neuron to increase GluR1-
containing AMPA receptors resulting in an increase in synaptic strength.  This 
increase in synaptic strength is maintained (Phase 2, ~ day 2) by initiating the 
Rab3A-dependent release of BDNF that signals to the postsynaptic neuron to 
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replace GluR1-containing AMPA receptors with GluR2-containing AMPA 
receptors.  Our model demonstrates a novel biphasic mechanism for the 
manifestation of homeostatic plasticity, and most importantly, whatever the range 
of underlying mechanisms of altered synaptic strength that can be triggered by 
chronic activity blockade, synaptic strength cannot be modulated in the absence 
of Rab3A.  
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Figure 1.  Potential mechanisms of homeostatic synaptic plasticity.  Chronic 
network hyperactivity could result in a decrease in presynaptic vesicle 
neurotransmitter concentration (1) and/or removal of postsynaptic AMPARs 
(2).  Chronic network silencing may cause an increase in presynaptic vesicle 
loading of neurotransmitter (3) and/or increased insertion of postsynaptic 
AMPARs (4).   
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Figure 2.  The Rab GTPase cycle.  
The Rab GTPase cycles between its 
“on” GTP-bound form where it 
associates with synaptic vesicles 
targeting them to the cell membrane 
and its “off” GDP-bound form where 
it dissociates from vesicles. 
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Figure 3.  Rab3A knock-out 
genotyping by PCR.  PCR 
genotyping of Rab3A-/- (left 
lane), Rab3A+/- (middle lane), 
and Rab3A+/+ (right lane). 
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Figure 4.  Rab3A earlybird genotyping.  A.  
Rab3A ebd-targeted PCR.  B.  Restriction 
digest of Rab3A ebd-targeted PCR amplicons 
showing Rab3A+/+ (left lane), Rab3A+/ebd 
(middle lane), and Rab3Aebd/ebd (right lane). 
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Figure 5.  Patch electrode on a 
cultured cortical pyramidal 
neuron. 
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Figure 6.  All mEPSCs recorded were 
AMPA receptor-mediated.  Blockade of 
AMPA receptors via CNQX abolishes all 
mEPSC activity which is restored upon 
removal of CNQX.      
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Figure 7.  Normally functioning Rab3A is necessary for the homeostatic 
increase in synaptic strength.  A.  Example recordings of Rab3A+/+ and 
Rab3Aebd/ebd mEPSCs from control neurons and neurons grown in TTX for 2 
days.  B.  Comparison of Rab3A+/+ and Rab3Aebd/ebd  mEPSC frequency in 
both conditions indicated revealed that Rab3Aebd/ebd diminished the significant 
increase in frequency.  * p = 0.030.  C.  The distribution of mEPSC amplitude 
increases with TTX-treatment in Rab3A+/+ neurons (left) and this effect is 
blocked in Rab3Aebd/ebd neurons (right).  D.  Quantification of mEPSC 
amplitude demonstrates that Rab3Aebd/ebd abolished the activity-dependent 
increase in amplitude.  * p = 0.007.  
 A. B. 
C. D. 
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Figure 8.  Rab3A is required for the homeostatic increase in synaptic strength.  
A.  Typical Rab3A+/+ and Rab3A-/- neuronal mEPSC recordings from cultures 
treated for 2 days with TTX and untreated sister cultures.  B.  Quantification of 
mEPSC frequency showing the diminished homeostatic increase in Rab3A-/- 
neurons.  * p = .005.  C.  The chronic TTX-induced shift to increased mEPSC 
amplitude is lost in Rab3A-/- neurons.  D.  Rab3A-/- blocks the homeostatic 
increase in amplitude.  * p = 0.0004.    
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Figure 9.  Potential Rab3A-dependent 
mechanisms for regulating the 
homeostatic increase in synaptic 
strength.  Rab3A may increase synaptic 
strength in a homeostatic manner by: (1) 
increasing neurotransmitter concentration 
loaded into vesicles, (2) regulating the 
presynaptic release of a molecule that, in 
turn, signals to increase postsynaptic 
AMPAR expression, (3) trafficking 
postsynaptic vesicles loaded with 
AMPARs to the membrane, or (4) 
controlling the release of glial-derived 
factors that signal to increase 
postsynaptic AMPAR numbers.      
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Figure 10.  Sensitivity to γ-DGG is independent of mEPSC amplitude and of 
TTX effect.  A.  The mean percent reduction of mEPSC amplitude in response 
to γ-DGG is not diminished in TTX-treated neurons.  B.  Scatter plot of each 
cell’s γ-DGG-induced % reduction of mEPSC amplitude vs. its pre-γ-DGG 
average amplitude demonstrating that the amount of γ-DGG inhibition is 
independent of initial mEPSC amplitude and of chronic silencing via TTX (R2 
= 0.08, p = 0.67).  C.  Example average mEPSC traces of individual neurons 
showing a γ-DGG insensitive control cell with a small basal mean amplitude 
(top, 15.0% reduction), a γ-DGG sensitive control cell with a large mean basal 
amplitude (middle, 50.5% reduction), and a γ-DGG sensitive TTX-treated cell 
with a large mean basal amplitude (bottom, 41.4% reduction).  
 
 
 
 
Figure 11.  Example images of surface GluR1 staining in untreated and TTX-treated cultures.  
Arrows indicate synapses (green = MAP2 (dendrite), red = GluR1, and white = VGLUT1).  Scale 
bars (white, lower right of each image) is equal to 5 μm. 
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Figure 12.  Chronic TTX treatment has variable effects on surface 
expression of GluR1-containing AMPA receptors.  A. Left, quantification of 
overall GluR1 puncta size in Rab3A+/+ cultures in response to TTX revealed 
no changes.  Right, breakdown of TTX effects on GluR1 cluster size of each 
wild-type culture.  B.  Left, overall GluR1 intensity in wild-type cultures did 
not change in response to TTX.  Right, breakdown of TTX treatment on 
GluR1 intensity of each wild-type culture.         
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Figure 13.  Individual experiment demonstrating a homeostatic 
increase in a culture’s mEPSC amplitude is not accompanied 
by an increase in that culture’s surface GluR1 expression.  A.  
TTX-induced increase in culture mEPSC amplitude.  Scatter 
plots of each dendrite’s GluR1 staining (open squares) and 
their mean staining (filled squares) showing no change in B. 
total GluR1 puncta size (left) or intensity (right), or C. synaptic 
GluR1 puncta size (left) or intensity (right). 
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Figure 14.  A second experiment demonstrating the same 
result as in Figure 13 – Despite a homeostatic increase in a 
culture’s mEPSC amplitude, there is no associated increase in 
that culture’s surface GluR1 expression.  A.  TTX-induced 
increase in culture mEPSC amplitude.  Scatter plots of each 
dendrite’s GluR1 staining (open squares) and their mean 
staining (filled squares) showing no change in B. total GluR1 
puncta size (left) or intensity (right), or C. synaptic GluR1 
puncta size (left) or intensity (right). 
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Figure 15.  A modest homeostatic increase in GluR1 expression is not 
prevented by loss of Rab3A.  A.  Quantification of overall GluR1 puncta size 
in Rab3A-/- cultures in response to TTX revealed a modest homeostatic 
increase in GluR1 puncta size.  B.  Breakdown of TTX effects on GluR1 
cluster size of each Rab3A-/- culture.           
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Figure 16.  Lack of inhibition of GluR1 homomers with NASPM further rules 
out GluR1 as a major mechanism underlying the homeostatic increase in 
synaptic strength.  A.  Bar graph showing NASPM does not block the TTX-
induced increase in mEPSC amplitude.  * p = 0.016, ** p = 0.008.  B.  Left 
(Neuron 1), example histogram plot of a neuron exhibiting inhibition of the 
homeostatic increase in mEPSC amplitude by NASPM highlighting the loss 
of the largest events after NASPM (29.6% reduction, pre-NASPM mean 
amplitude = 22.0 pA; red bars = distribution of pre-NASPM events, black 
line = distribution of events with NASPM).  Right (Neuron 2), in other cells, 
amplitude was insensitive to NASPM (1.4% increase, pre-NASPM mean 
amplitude = 18.6 pA).  C.  Bar graph showing NASPM inhibition of the 
homeostatic increase mEPSC frequency (* p = 0.017, # p = 0.027, ** p = 
0.006).  D.  Scatter plot showing a weak (R2 = 0.19) but significant (p = 
0.01) correlation between the average of the largest 25 events and the 
sensitivity to NASPM.  E.  NASPM often caused a clear reduction in 
mEPSC frequency without affecting amplitude (traces are from Neuron 2, 
above)    
 
 
 
 
Figure 17.  Example images of surface GluR2 staining in untreated and TTX-treated cultures.  
Arrows indicate synapses (red = GluR2, and white = VGLUT1).  Scale bars (white, lower right of 
each image) are equal to 5 μm. 
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Figure 18.  Synaptic GluR2-containing AMPA receptors had a modest 
homeostatic increase in expression that was blocked by loss of Rab3A.  
Quantification of overall synaptic GluR2 puncta size in Rab3A+/+ cultures 
showed a modest trend towards increasing after chronic TTX treatment 
(A, left) that was less obvious in Rab3A-/- cultures (C, left).  Line-series 
plot of TTX effects on synaptic GluR2 cluster size of each Rab3A+/+ 
culture (A, right) and Rab3A-/- culture (C, right).  Quantification of overall 
synaptic GluR2 intensity in response to chronic TTX treatment revealed 
no changes in Rab3A+/+ cultures (B, left) or in Rab3A-/- cultures (D, left).  
Line-series plots of the TTX effect on synaptic GluR2 expression in 
individual experiments on Rab3A+/+ cultures (B, right) and Rab3A-/- 
cultures (D, right). 
 
 
 
Figure 19.  Individual physiology-GluR2 immunohistochemistry correlation experiments.  A, C, and E.  TTX 
effects on mEPSC amplitude from each Rab3A+/+ experiment, and their corresponding synaptic GluR2 
expression profiles (B, D, and F; hollow squares represent single dendrites, filled squares represent means for 
all dendrites in each condition).  G, I, and K.  mEPSC amplitude responses to chronic TTX treatment in 
individual Rab3A-/- cultures, and their corresponding synaptic GluR2 immunohistochemistry experiments (H, J, 
and L).  Percent changes from untreated (CON) to TTX-treated (TTX) conditions are in red. 
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Figure 20.  Neuronal Rab3A is responsible for the homeostatic increase 
in mEPSC amplitude.  A.  Culturing strategy using glial feeder layers and 
neurons from wild-type and Rab3A-/- mice.  B.  Wild-type (WT) neurons 
grown on WT glia exhibit a homeostatic increase in mEPSC amplitude.    
* p = 0.023.  C.  WT data from Figure 8 for reference of chronic TTX effect 
on synaptic strength in our initial culturing strategy.  D.  WT neurons on 
Rab3A-/- (KO) glia show a TTX-induced increase in mEPSC amplitude.     
* p = 0.005.  E.  Loss of neuronal Rab3A (KO neurons on WT glia) blocks 
the homeostatic increase in mEPSC amplitude.  F.  KO data from Figure 
8 for reference showing that loss of Rab3A blocks the homeostatic 
increase in synaptic strength in our initial cultures.  
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Figure 21.  Rab3A-dependent model of a biphasic mechanism for the 
homeostatic increase in synaptic strength.  Phase 1, or the Induction 
Phase (~ day 1), is initiated by a chronic decrease in network activity (1) 
triggering glial release of TNFα (2) that signals to the postsynaptic neuron 
(3) to increase GluR1 incorporation into the membrane (4).  In the 
transition from day 1 to day 2 after activity blockade (5), Phase 2, or the 
Maintenance Phase, is initiated by triggering Rab3A-dependent release of 
BDNF from the presynaptic neuron (6), which travels across the synaptic 
cleft activating a signaling cascade in the postsynaptic neuron (7) to 
replace GluR1 receptors and increase GluR2 levels (8).    
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Article Species Age Tissue Prep DIV 
Type of 
Block 
Length 
of Block 
Mechanism 
Method 
Quantified 
Aoto et al., 
2008 
rat E22 Hippo Dissociated 14-15 TTX 24 hrs GluR1   
Soden & 
Chen, 2010 
mouse P0-P1 Hippo Dissociated ~14 TTX 24 hrs GluR1 Western 
Shepherd et 
al., 2006 
rat E18-E19 
Hippo 
Cortical 
Dissociated 12-14 TTX 48 hrs GluR1 
Intensity 
Western 
Correa et 
al., 2012 
mouse P0-P1 Hippo Dissociated 15-18 TTX 24 hrs GluR1 Intensity 
Thiagarajan 
et al., 2005 
rat P2-P4 Hippo Dissociated 16-17 receptor 24 hrs GluR1 Western 
Gong et al., 
2007 
mouse P0 Cortical Dissociated 14-17 receptor 24 hrs GluR1 Western 
Ju et al., 
2004 
rat E18 Hippo Dissociated 5-8 TTX 24 hrs GluR1 Synaptic 
Stellwagen 
& Malenka, 
2006 
mouse P0 Hippo Dissociated 13-15 TTX 48 hrs GluR1 Area 
Hou et al., 
2008 
rat E18 Hippo Dissociated ~14 Kir2.1 24 hrs GluR1 Intensity 
Goel et al., 
2006 
rat 5 wks 
Visual 
cortex 
Slice na 
Dark 
rearing 
1 wk GluR1 Western 
Goel et al., 
2011 
mouse P21 
Visual 
cortex 
Slice na 
Dark 
exposure 
24 hrs GluR1 Western 
Sun & Wolf, 
2009 
rat P1 
NAc/PFC 
co-culture 
Dissociated 
2-3 
wks 
receptor 24-72 hrs GluR1 & GluR2 
Surface Area 
Surface # 
Synaptic 
NonsynapticCell
ular 
Wierenga et 
al., 2005 
rat P3-P4 Cortical Dissociated 7-10 TTX 48 hrs GluR1 & GluR2 
Intensity 
Synaptic 
Nonsynaptic 
Cingolani et 
al., 2008 
rat P0 Hippo Dissociated 9-15 TTX 48 hrs GluR2 
Relative 
fluorescence 
Gainey et 
al., 2009 
rat P2-P4 Cortex Dissociated 6-10 TTX 24 hrs GluR2 Pharmacology 
 
                 Table 1.  Summary of studies examining the involvement of AMPA receptors in homeostatic  
                                 synaptic plasticity.       
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Table 2.  List of antibodies used for immunohistochemistry experiments.  GluR1 and GluR2 expression were  
examined in separate experiments.  
 
 
1° Antibody Labels Species Conc. Supplier 2° Antibody Reactivity Conc. Supplier 
anti-MAP2 (mono) Soma & dendrites Mouse 1:300 Sigma 488 anti-mouse 1:225 Jackson 
anti-VGLUT1 
Presynaptic 
terminals 
Guinea pig 1:4000 Chemicon Cy3 anti-guinea pig 1:225 Jackson 
anti-GluR1 GluR1 receptor Rabbit 1:10 EMD Millipore Cy5 (649) anti-rabbit 1:225 Jackson 
Anti-MAP2 Soma & dendrites Chick 1:2500 Abcam 488 Anti-chick 1:225 Jackson 
anti-VGLUT1 
Presynaptic 
terminals 
Rabbit 1:4000 Synaptic Systems Cy5 anti-rabbit 1:225 Jackson 
anti-GluR2 GluR2 receptor Mouse 1:40 EMD Millipore CY3 Anti-mouse 1:225 Jackson 
